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ABSTRACT 
Pediatric obesity has reached epidemic proportions. Reducing obesity among 
children is expected to lower their likelihood of being obese as adults and, therefore, 
lower their cardiovascular and metabolic risk profile in adulthood including hypertension, 
dyslipidemia, type II diabetes, heart disease, and stroke. 
Pediatric obesity among ages 2–19 is defined as a body mass index (BMI) greater 
than or equal to the 95th percentile for age and gender as defined according to the CDC 
BMI-for-age growth charts. Risk factors for obesity are present as early as birth, 
suggesting exposures at different stages of the life cycle are important to study. The 
primary objective of this thesis was to evaluate exposures throughout childhood and 
evaluate their association with both weight and metabolic status.  
Study 1 examined the relationship between physical activity and metabolic 
syndrome in overweight and obese youth ages 12–19. We found that even modest 
amounts of moderate to vigorous physical activity were associated with a reduction in 
risk of metabolic syndrome, with time spent in vigorous physical activity driving the 
association. 
  viii 
Study 2 explored the relationship between environmental tobacco smoke (ETS) 
exposure and childhood overweight and obesity in 3–6 year old children. We observed 
that ETS has a positive association with risk of overweight/obesity, with a dose-response 
effect observed. 
Study 3 examined the relationship between maternal antibiotic use during 
pregnancy and infant birthweight. We did not observe any association between maternal 
antibiotic use and birthweight or BW/GA-z (birthweight adjusted for gestational age z-
score), but we did observe a reduction in risk of SGA (small for gestational age) for 
infants exposed to antibiotics during gestation. This association was most evident among 
third trimester users. 
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1. INTRODUCTION 
Approximately 17% of all children and adolescents ages 2–19 are obese with 
prevalence nearly equivalent in boys and girls (16.9% vs. 17.1%).1,2 From 1999–2014, 
the obesity rates increased from 14.0% to 16.9% for boys and from 13.8% to 17.1% for 
girls.1,2 Reducing obesity among children is expected to lower their likelihood of being 
obese as adults and, therefore, lower their cardiovascular and metabolic risk profile in 
adulthood including hypertension, dyslipidemia, type II diabetes, heart disease, and 
stroke.3 Risk factors for obesity can be present as early as birth. Low birthweight (LBW) 
and small for gestational age (SGA) infants have a more rapid postnatal catch up period 
that has been shown to be associated with overweight in early infancy.4 LBW has also 
been linked to overweight, obesity, increased risk of cardiovascular disease, and type II 
diabetes in adulthood.5 High birthweight (HBW), defined as birthweight >4,000 grams 
(or 8.8 pounds), is often the result of the mother gaining more than the recommended 
amount of weight during pregnancy and has also been shown to be associated with 
increased risk for childhood obesity by age 4.6,7 
Pediatric obesity in 12–19 year olds is defined as a body mass index (BMI = 
weight(kg)/[height(m)2])  greater than or equal to the 95th percentile for age and gender 
according to the CDC BMI-for-age growth charts.8 The CDC BMI-for-age growth charts 
reflect the distribution of BMI in a reference population. The reference population used to 
calculate the growth curves consisted of data from the National Health Examination 
Survey (NHES) II (1963–1965) and III (1966–1970) and NHANES I (1971–1974), 
NHANES II (1976–1980) and NHANES III (1988–1994).9 Overweight in children is 
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defined as BMI-for-age between the 85th and 95th percentiles as defined by the 
distribution in the reference population. These criteria differ for children and adults. For 
adults, overweight is defined as BMI 25–29.9, and obesity is defined as BMI ≥30.10 
These adult criteria are not appropriate to apply to children and teens because the amount 
of body fat changes with age and differs between girls and boys.8 
Many causes of childhood obesity have been explored, including poor diet, 
sedentary lifestyles, infant feeding practices, maternal smoking during pregnancy, and 
socioeconomic status. The literature on this topic is emerging and is not without 
limitations. This thesis explores several understudied exposures across different periods 
of childhood and their relationship with body size, applying methodologies and analytical 
strategies to strengthen the evidence base for three specific hypotheses. The first study 
examines the association between physical activity and metabolic syndrome among 
overweight and obese adolescents in NHANES 2007–2012. The second study, also using 
NHANES 2007–2012, assesses exposure to environmental tobacco smoke and its 
association with pediatric overweight/obesity. The third study, using data from the Birth 
Defects Study, examines maternal antibiotic use during pregnancy and its association 
with infant birthweight. 
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2. THE ASSOCIATION BETWEEN PHYSICAL ACTIVITY AND METABOLIC 
SYNDROME IN ADOLESCENTS AGES 12–19 IN NHANES 2007–2012 
2.1 INTRODUCTION 
Obesity is a major risk factor for cardiovascular disease, which is rooted in some 
individuals in childhood. Overweight and obese children are more likely than their 
normal weight peers to be overweight and obese adults. Among 6–8 year olds with a BMI 
≥95th percentile in the Bogalusa Heart Study, 83% of females and 78% of males became 
obese in adulthood.1 However, evidence suggests that not all obese individuals share the 
same risk of metabolic or cardiovascular disease. Individuals categorized as obese based 
on BMI can remain free of metabolic syndrome (MetS), a clustering of 
hyperglycemia/insulin resistance, obesity, and dyslipidemia, and thereby carry a lower 
risk for cardiovascular disease and type II diabetes compared to their peers with MetS.2 
Identifying those at greatest risk for these comorbidities can increase efficiency for 
intervention and help identify those most in need of and most likely to benefit from 
intervention. Studying adolescents (ages 12–19) is particularly important, as they are 
likely to carry the dietary and physical activity habits they develop at this age with them 
into adulthood.3 
More research has been done on MetS in adults than in children. Until recently, 
there were no clearly established guidelines defining MetS in children because puberty 
has an effect on fat distribution and insulin sensitivity and secretion.4 In 2007, the 
International Diabetes Federation (IDF) published an age-specific set of guidelines for 
diagnosing MetS in children based on the following risk factors: waist circumference, 
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blood pressure, triglycerides, HDL-cholesterol, and fasting glucose (see Appendix 1)5. 
Physical activity is one behavioral factor thought to decrease the risk of MetS. 
However, a recent study shows fewer than half of adolescents ages 12–19 are engaging in 
the recommended amount of physical activity (≥1 hour per day) and there is substantial 
variability in meeting these guidelines by race/ethnicity.6 In this cross-sectional study 
analyzing 987 adolescents ages 12–19 in NHANES 2011–2012, only 32% of adolescents 
were engaging in at least one hour of physical activity on a daily basis. Multivariable 
logistic regression models adjusted for age, sex, BMI, parental marital status, and 
household poverty ratio showed that Hispanics were 33% less likely than whites to meet 
the PA guidelines (OR=0.67; 95% CI: 0.43, 1.02), non-Hispanic Blacks were 15% less 
likely than whites to meet the PA guidelines (OR=0.85; 95% CI: 0.60, 1.20), and Asians 
were 42% less likely than whites to meet the PA guidelines (OR=0.58; 95% CI: 0.36, 
0.92).6 
After the publication of IDF criteria for MetS in children and adolescents, a few 
studies on metabolic syndrome and physical activity in children and adolescents were 
published. A cross-sectional study of 181 8–17 year olds with a BMI ≥85th percentile 
enrolled in a pediatric weight management clinic in Canada evaluated predictors of 
metabolically healthy obesity (MHO), defined as the absence of each of the following 
risk factors: SBP or DBP ≥ 90th percentile for age, sex, and height; TG ≥ 1.25 mmol/L; 
HDL-C ≤ 1.02 mmol/L; glucose ≥ 5.6 mmol/L).7 Moderate-to-vigorous physical activity 
was defined as average minutes per day (over the course of a 4 to 7 day period, with at 
least one weekend day) spent performing higher intensity sports and activities. 
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Participants self-reported sports and activities in an activity log. Minutes per day spent in 
activities identified by researchers as moderate, hard, or very hard in intensity were 
summed and used to define minutes per day spent performing moderate-to-vigorous 
intensity PA.7,8 For every standard deviation increase in MVPA (47 minutes/day), an 
80% (OR=1.80; 95% CI: 1.24, 2.62) increase in odds of MHO was observed. This study 
was limited by a racially and socioeconomically homogeneous study population 
comprised of primarily Caucasian youths from middle- to upper-class households, and 
the inability to evaluate the effects of sexual maturation. 
Another study looked at the relationship between sedentary behavior (physical 
inactivity) and MetS in a group of 6–14 year old children and adolescents.9 MetS was 
defined as having at least 3 of the following 5 criteria: WC, TG, BP (SBP or DBP), and 
blood glucose >90th percentile for age and sex, and HDL-C <10th percentile for age and 
sex. Authors reported an increased risk of MetS among children and adolescents who 
were sedentary for 5 or more hours daily outside of school compared to those who were 
sedentary for <5 hours per day outside of school (OR=2.30; 95% CI: 1.30, 4.30).9 
Physical inactivity, or time spent sedentary, was reported by the parent and defined as 
time spent outside of school watching television, sitting at the computer, or playing video 
games. However, this study was conducted in an Italian population and the prevalence of 
MetS was low (4.9% in boys, 3.4% in girls), limiting generalizability, especially to a 
racially and ethnically heterogeneous population like the US. 
Other observational cohort studies reported similar results. In a cross-sectional 
study, Heshmat, et al.10 reported that a high level of physical activity (compared to low) 
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was associated with increased levels of HDL-C, lower BMI z-scores, lower total 
cholesterol, and lower blood pressure in a nationally representative sample of 5,625 
Iranian children and adolescents ages 10 to 18. A high level of physical activity was 
defined as reporting engaging in activity for at least 30 minutes in duration that might 
lead to heavy sweating or large increases in breathing or heart rate for at least 3 days in 
the past week, whereas low physical activity was defined by fewer than 3 days of the 
previously mentioned physical activity in the past week.10 In another cross-sectional 
study, Cardenas, et al.11 reported that mild leisure time physical activity (LTPA) 
compared to intense LTPA was positively associated with a continuous score assessing 
cardiometabolic risk, with the association being strongest in overweight and obese youths 
in their study of 1,309 Mexican children ages 5 to 17. LTPA was categorized into tertiles 
(mild: ≤21.72, moderate: 21.73–51.3, and intense: >51.3 mets/hour/week). Metabolic 
equivalents were calculated from self-report of days per week and minutes or hours per 
day engaged in sports activities during leisure time, walking for transportation, and 
popular games.11 Lastly, Neto, et al.12 reported that time spent in MVPA was inversely 
associated with a continuous risk score for metabolic syndrome in a study of 391 
Brazilian youths ages 10 to 18. Physical activity was measured with an accelerometer 
worn by the subjects for 7 consecutive days on their hip. Subjects with at least 4 full days 
of wear time (≥600 mins/day) were included in the analysis. The counts obtained in 
different activities were converted into metabolic equivalents (METs) and activities were 
categorized as light (1.5≤METs<3), moderate (3≤METs<6) and vigorous (≥6 METs). 
These authors developed a receiver operating characteristic (ROC) curve suggesting that 
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adolescents should perform at least 80 minutes per day of MVPA to minimize the risk of 
MetS.12 
Few studies have examined the association between physical activity and MetS in 
an adolescent population, and these studies have been limited by homogeneous study 
populations. This study set out to examine the association of physical activity and MetS 
among adolescents ages 12–19 in a racially-diverse, high-risk (BMI ≥ 85th percentile for 
age and gender) population and to evaluate the effects of puberty on this association in 
females. 
 
2.2 METHODS 
 2.2.1 Data Source 
The National Health and Nutrition Examination Survey (NHANES) data from 
2007–201213 was used for this analysis. NHANES was designed to assess the health and 
nutritional status of adults and children in the United States. It is unique in that it 
combines interviews, physical exams, measured anthropometry, and biomarker data. 
NHANES began as a series of surveys in the 1960s and in 1999 became an annual 
survey. NHANES constitutes a nationally representative sample of about 5,000 
individuals in each survey year.14  
2.2.2 Study Population and Design 
This cross-sectional NHANES investigation uses data from 3,750 males and non-
pregnant females ages 12–19 who were interviewed about physical activity and diet and 
  
9 
had clinical exams including blood draws and measurement of weight, height, and waist 
circumference. Participants ages 12 and older who were examined in the morning session 
and who had completed at least a 9 hour fast were asked to participate in an oral glucose 
tolerance test (OGTT). Restricting the sample to participants who fasted, were examined 
in the morning session, and who completed an OGTT reduced our sample, however, it 
was necessary in order to accurately classify those with impaired fasting plasma glucose 
and diabetes mellitus (rather than relying on self-report of previous DM diagnosis). This 
subgroup yielded 1,603 participants. Of these, 611 children (38%) were overweight or 
obese (defined as BMI ≥85th percentile for age and sex according to the 2000 CDC 
Growth Charts for the United States).15 Among them, 78 were excluded from the analysis 
because they had at least one missing value for metabolic syndrome (MetS), MVPA, age, 
sex, race, current smoking status, 2-day dietary recall, and food insecurity. The remaining 
533 adolescents constituted the study population.  
2.2.3 Study Variables 
Outcome-Metabolic Syndrome (MetS) 
The primary outcome of interest was metabolic syndrome (MetS). MetS was 
defined with the aid of the metabolic syndrome guidelines established by the IDF5 (see 
Appendix 1). MetS was defined as having at least 3 of the following 5 metabolic risk 
factors: (1) abdominal obesity based on waist circumference, (2) triglycerides (TG) ≥150 
mg/dL or use of cholesterol lowering medication, (3) high density lipoprotein cholesterol 
(HDL-C) <40 mg/dL for 12-15 year olds; HDL-C <40 mg/dL for males 16+ and HDL-C 
<50 mg/dL for females 16+ or use of cholesterol lowering medication, (4) systolic blood 
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pressure (SBP) ≥130 mm/Hg and/or diastolic blood pressure ≥85 mm/Hg or use of blood 
pressure lowering medication, (5) fasting glucose ≥5.6 mmol/L or diagnosis of type II 
diabetes or taking insulin or pills to lower blood sugar.5 Waist circumference cut-offs 
vary according to age. For 16–18 year olds, adult criteria were used: ≥ 94 cm for males 
and ≥ 80 cm for females. For 12–15 year olds, the lower value was chosen between the 
adult criteria and the cut-point for the 90th percentile for age and sex.5, 16 Blood 
specimens, OGTT, anthropometry measures, and blood pressure readings were collected 
in the mobile examination center (MEC) by trained health technicians. Blood pressure 
measurements were taken after the participant had rested quietly for 5 minutes and their 
maximum level of inflation (MIL) was determined. Three consecutive readings were 
taken; a fourth was made if one of the first three were interrupted or incomplete. 
NHANES protocol, standardization procedures, and additional data collection 
information are documented in detail elsewhere.17–22 
In some cases, participants had missing values for one or two of the five risk 
factors, but were still appropriately classified as having MetS or no MetS based on the 
other non-missing values. Those 8 study subjects were included. 
 
Exposure- Physical Activity 
The primary exposure of interest was minutes per week engaged in recreational 
moderate-to-vigorous physical activity (MVPA), which is MVPA unrelated to work or 
transportation. The 2008 Physical Activity Guidelines for Americans Summary states that 
children and adolescents should engage in at least 60 minutes of physical activity daily.23 
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Additionally, at least three of these days should include exercise of vigorous intensity. 
NHANES collected data on moderate and vigorous physical activity separately in a 
questionnaire.14 Participants were asked, “Do you do any vigorous-intensity sports, 
fitness, or recreational activities that cause large increases in breathing or heart rate like 
running or basketball for at least 10 minutes continuously?”  As a follow up, participants 
were asked, “In a typical week, on how many days do you do vigorous-intensity sports, 
fitness, or recreational activities?”  Lastly, participants were asked “How much time do 
you spend doing vigorous-intensity sports, fitness, or recreational activity on a typical 
day?” The same line of questioning was asked for moderate activity. Moderate-intensity 
sports, fitness, or recreational activities were referred to as “activities that cause a small 
increase in breathing or heart rate such as brisk walking, bicycling, swimming, or golf for 
at least 10 minutes continuously”.14 Minutes per week engaged in vigorous recreational 
physical activity was calculated by multiplying the days per week by the minutes per day 
the participant reported engaging in vigorous recreational physical activity. The same 
calculation was performed for minutes per week engaged in moderate physical activity. 
Minutes per week engaged in vigorous recreational physical activity was added together 
with minutes per week engaged in moderate recreational physical activity to get the 
minutes per week engaged in MVPA. MVPA was categorized according to quartiles of 
the data: (1) <30 minutes per week, (2) 30 to 179 minutes per week, (3) 180–479 minutes 
per week, and (4) ≥480 minutes per week. Minutes per week engaged in moderate (MPA) 
and vigorous PA (VPA) were also examined separately. Categories were defined based 
on quartiles; however, the median for MPA was 0, therefore 3 categories were examined: 
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(1) 0 minutes per week, (2) >0 to 150 minutes per week, and (3) >150 minutes per week. 
More than a quarter of subjects had 0 minutes of VPA resulting in some unevenly sized 
exposure categories: (1) 0 minutes per week, (2) >0 to 90 minutes per week, (3) >90 to 
315 minutes per week, and (4) >315 minutes per week. 
Covariates 
Potential confounders included age, sex, race (white/non-white), SES of the 
parents (measured by the family monthly poverty level index which is a ratio of monthly 
family income to the Department of Health and Human Services poverty guidelines 
specific to family size), dietary quality (Healthy Eating Index 2010 (HEI-2010) total 
score23; sugar intake (g); total energy (kcal); fast food (number of meals per week)), food 
insecurity (family received food stamp benefit in the past 12 months) and current 
smoking status of the adolescent (Y/N). Additionally, whether or not the female had an 
early first period (first period prior to 12 years of age: Y/N, females who had not reported 
a first period were considered as not having an early first period) was considered for 
female participants. Dietary intake was measured using two 24-hour recalls. The first 
recall was assessed in the 24 hours prior to the in-person interview in the mobile 
examination center (MEC) and the second was collected 3–10 days later via telephone.20 
Sugar intake (g) and total energy (kcal) were calculated by averaging the total sugar and 
total energy from each of the two 24-hour recall periods. Nutrient estimates were 
obtained using the USDA’s Food and Nutrient Database for Dietary Studies (FNDDS).25 
The Healthy Eating Index (HEI) measures overall diet quality. It consists of 12 
components: (1) total fruit, (2) whole fruit, (3) total vegetables, (4) greens and beans, (5) 
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whole grains, (6) dairy, (7) total protein foods, (8) seafood and plant proteins, (9) fatty 
acids, (10) refined grains, (11) sodium, and (12) empty calories. The scores of each 
component are summed together to create a total score (maximum possible value of 100), 
with higher values indicating an overall better diet quality. Validation of the HEI-2010 
found overall adherence to dietary guidelines to be relatively poor in the NHANES 
population, with an average score of 45.4 in young adults, compared to 56.1 in older 
adults.26    
 Information on food security came from the Family Questionnaire and was 
reported by the head of the household (18+ or emancipated minor). Information on 
demographics, SES, dietary behavior, and health and medical history was reported on the 
Sample Person Questionnaire, where participants 16 and older were interviewed directly, 
and information for participants <16 were reported by an adult proxy.14 
2.2.4 Data Analysis 
These data were analyzed using SAS statistical software (version 9.3, SAS 
Institute). NHANES survey weights were not taken into account given the specific 
subsample used. Additionally, the aim was to assess association and not prevalence; 
therefore, results are specific to this sample.27, 28 
Descriptive analyses were conducted to examine the distribution and frequencies 
of the exposure and outcome variables as well as the covariates. Bivariate frequency 
tables between each potential confounder, outcome, and exposure were examined. Means 
and standard deviations were calculated for continuous variables. The mean of the 
continuous MVPA variable (measured in minutes/week) was examined by MetS (yes/no).  
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Logistic regression was used to examine both the crude and adjusted measure of 
association between MetS and quartiles of MVPA with the lowest level (<30 minutes per 
week) serving as the reference category. Potential confounders were added to the model 
one at a time and the relationship with the exposure and outcome was assessed. If the 
addition of the confounder altered the measure of association by at least 10%, the 
confounder was left in the model; if not, it was removed. When a final model was 
selected, the confounders previously excluded were reexamined before deciding on the 
final model. 
Stratified analyses were conducted to examine effect measure modification 
(EMM) by sex (male vs. female) and food insecurity (received food stamps in last 12 
months: Yes/No). Sample size limitations prohibited stratification by current smoking 
status (Y/N) and race (white vs. nonwhite). 
Separate analyses were also conducted to examine the independent association of 
moderate physical activity with MetS and vigorous physical activity with MetS. In both 
cases, the lowest level of activity (0 minutes per week for both MPA and VPA) served as 
the reference category. 
 
2.3 RESULTS 
Among the 533 overweight or obese adolescent 12–19 years old who had fasting 
laboratory data in NHANES 2007–2012 and non-missing values for covariates, 82 
(15.4%) met the criteria for metabolic syndrome (MetS). Demographic characteristics are 
presented by MetS status in Table 2.1. Adolescents identified as having MetS engaged in 
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103 fewer minutes of MVPA per week compared to their peers who did not have MetS. 
Adolescents with MetS were more likely to be older (16.4 vs/ 15.2), more likely to be 
male (68.3% vs. 51.7%), to smoke (19.5% vs. 12.0%, respectively), and to belong to a 
food insecure home (31.7% vs. 27.5%). BMI percentile was 2.9 percentage points higher 
in the MetS group compared to the no MetS group. Additionally, adolescents with MetS 
consumed, on average, 300 kcal and 27 g of sugar more per day than adolescents without 
MetS and the quality of their overall diet was slightly lower. 
Table 2.2 shows the prevalence of individual metabolic risk factors by MetS in 
this study sample. The most prevalent risk factor among those with MetS was abdominal 
obesity (93.8%), followed by low HDL-C (85.2%), diabetes or elevated fasting plasma 
glucose (65.9%), high triglycerides (63.0%), and high blood pressure (23.8%). Among 
those with MetS, 75.6% had three risk factors, 20.7% had 4 risk factors, and 3.7% had all 
5 risk factors. Of note, only about one in four overweight youths without MetS had zero 
risk factors (23.7%). Almost half (44.6%) had one risk factor of concern and another one-
third of this subgroup (31.7%) had two risk factors. Adolescents with MetS had, on 
average, systolic blood pressure 8 mmHg higher, diastolic blood pressure 5 mmHg 
higher, triglycerides 82 mg/dL higher, HDL-cholesterol 12 mg/dL lower, fasting glucose 
8 mg/dL higher, and waist circumference 14 cm greater than their peers who did not have 
MetS. 
Table 2.3 examines the distribution of demographic covariates and the prevalence 
of individual metabolic risk factors by category of MVPA (<30 minutes/wk, 30–179 
minutes/wk, 180–479 minutes/wk, 480+ minutes/wk). The highest MVPA category 
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(480+ minutes/week) was largely male (67.6%). The distribution of race/ethnicity was 
similar across activity levels. The lowest activity group (<30 minutes/week) had the 
highest prevalence of smokers (17.9%), and was on average older than the other activity 
groups. As minutes per week engaged in MVPA increased, the prevalence of abdominal 
obesity and low HDL consistently decreased. A U-shaped relationship was observed 
between diabetes/elevated fasting plasma glucose, high TG, high BP, total number of 
metabolic risk factors and categories of MVPA. The prevalence of MetS (3+ risk factors) 
was 24.3% among participants engaging in <30 minutes of MVPA per week, 12.9% 
among participants engaging in 30–179 minutes per week, 10.3% among participants 
engaging in 180–479 minutes per week, and 15.1% among those engaging in 480+ 
minutes per week.    
There was little variability in diet quality between adolescents with and without 
MetS (Table 2.4) as measured by the HEI-2010 based on two days of dietary recall data, 
however, overall diet quality for both groups was poor with adolescents with MetS 
scoring 44.2 for HEI-2010 total and adolescents without MetS scoring 46.9. Adolescents 
with MetS ate more refined grains, as indicated by their lower score, compared to 
adolescents without MetS (HEI-2010 score 4.4 vs. 5.0 out of 10, respectively) and 
consumed more empty calories (HEI-2010 score 10.5 vs. 11.8 out of 20, respectively). 
Higher levels of MVPA were associated with a lower risk of MetS (Table 2.5). 
After adjusting for age, sex, and average daily grams of sugar consumed, the effect was 
attenuated, but the inverse association remained. In the fully adjusted model, the MVPA 
OR (95% CI) for 30–179 minutes per week was 0.56 (0.27, 1.15); for 180–479 minutes 
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per week was 0.41 (0.20, 0.82), and for 480+ minutes per week was 0.51 (0.26, 0.99). 
White race, current smoking status, food insecurity, and HEI-2010 total score were not 
associated with MetS and when added to the model, did not appreciably change the effect 
estimates; therefore, these covariates were not included in the final model. 
Models stratified by sex showed a slightly different effect in males as compared 
to females, with more evidence of a dose-response effect seen in females. However, 
confidence intervals for females were wider due to the smaller number of females with 
MetS. In the fully adjusted model for males (adjusted for age and average daily 
consumption of sugar) (Table 2.6a), the MVPA OR (95% CI) for 30–179 minutes per 
week was 0.50 (0.20, 1.24); for 180–479 minutes per week was 0.30 (0.12, 0.75), and for 
480+ minutes per week was 0.54 (0.24, 1.18). In the fully adjusted model for females 
(adjusted for age, average daily consumption of sugar, and early age at first period (<12 
years old)) (Table 2.6b), the MVPA OR (95% CI) for 30–179 minutes per week was 0.68 
(0.21, 2.20); for 180–479 minutes per week was 0.73 (0.24, 2.21), and for 480+ minutes 
per week was 0.26 (0.05, 1.39). Early age at first period did not appreciably alter the 
association between MVPA and MetS in this sample of overweight and obese 12 to 19-
year-old females. 
Among those with food insecurity (n=150) (Table 2.7a), in the model adjusted 
for age, sex, and average daily sugar consumption, the MVPA OR (95% CI) for 30–179 
minutes per week was 0.27 (0.05, 1.49); for 180–479 minutes per week was 0.65 (0.21, 
2.04), and for 480+ minutes per week was 0.33 (0.08, 1.33). In the fully adjusted model 
for participants who were not food insecure (n=383) (Table 2.7b), the MVPA OR (95% 
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CI) for 30–179 minutes per week was 0.73 (0.32, 1.67); for 180–479 minutes per week 
was 0.31 (0.12, 0.79), and for 480+ minutes per week was 0.61 (0.28, 1.32). There was 
no evidence of a dose-response relationship for MVPA and MetS in either food insecurity 
group. 
Models exploring moderate and vigorous activity separately (Tables 2.8a and 
2.8b) showed that MPA did not have an independent association with MetS. In the fully 
adjusted model, the MPA OR (95% CI) for >0 to 150 minutes per week was 1.30 (0.70, 
2.30) and the OR (95% CI) for >150 minutes per week was 0.96 (0.51, 1.79), relative to 
the reference group of 0 minutes per week. VPA appeared to be driving the observed 
association between MVPA and MetS. In the fully adjusted model, the VPA OR (95% 
CI) for >0 to 90 minutes per week was 0.71 (0.27, 1.85); for >90 to 315 minutes per week 
was 0.58 (0.30, 1.12); and for >315 minutes per week was 0.51 (0.27, 0.98), all relative to 
the reference group of 0 minutes per week. The model for VPA was the only time we saw 
a true dose-response effect, with a steady reduction in risk of MetS with increasing time 
spent engaging in VPA (Cochran-Armitage one-sided test for trend, p=0.02). 
 
2.4 DISCUSSION 
In this diverse sample of overweight and obese 12–19 year olds, we observed that 
even modest amounts of moderate-to-vigorous physical activity have an inverse 
association with clusters of cardiovascular risk factors known as the metabolic syndrome. 
This association remained after adjustment for age, sex, and average daily sugar 
consumption, which were observed to be predictors of MetS. The inverse relationship 
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was present among subgroups of boys, girls, and those with and without food insecurity, 
though confidence intervals were wider due to small numbers in the subgroup analyses. 
We observed that vigorous physical activity was driving this association. We observed an 
independent, inverse association between VPA and MetS, but did not observe an 
association for MPA. However, the magnitude of the association was strongest when 
combining moderate and vigorous physical activity together, suggesting a synergistic 
effect between the two. Our findings are consistent with other studies that have shown an 
inverse association between physical activity and metabolic risk factors.7, 29–32 
One such study that examined the relationship between physical activity and 
metabolic risk factors in youths ages 8 to 17 aimed to determine independent predictors 
of metabolically healthy obesity (MHO), defined as the absence of all metabolic risk 
factors. Conversely, metabolically unhealthy obesity (MUO) was defined as having at 
least 1 metabolic risk factor.7 Prince, et al. reported that 21.5% of participants were 
MHO, defined as the absence of any cardiovascular risk factors; in our study 107 of 533 
(20.1%) participants had 0 metabolic risk factors. In their study, MVPA emerged as the 
strongest independent predictor of MHO, after adjusting for age and sex. Investigators 
reported that for every standard deviation increase in MVPA (47 min/day), there was an 
80% increase in the odds of a participant being in the MHO group.7 Our study defined 
MetS as having 3 or more metabolic risk factors and the absence of MetS was defined as 
having <3 metabolic risk factors; however, with slightly different outcomes, our model 
adjusted for age and gender only (Model 2, Table 2.5) showed an association of similar 
magnitude. Additionally, our study examined MVPA as minutes per week, where Prince, 
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et al. examined MVPA with respect to minutes per day. We observed a stronger 
association between MVPA and MetS in our model adjusted for age and gender; 
however, once we added a dietary measure (average daily grams of sugar consumed), the 
association was slightly attenuated. Physical activity models in the study by Prince, et al. 
did not adjust for dietary factors. Instead, diet was examined separately as a primary 
predictor in models adjusted for age and gender. Had investigators adjusted their PA 
models for diet, it is likely they would have noted some attenuation of their observed 
effect.  
In a longitudinal, prospective study of European preadolescents (the IDEFICS 
cohort), 3,348 children ages 3 to 10.9 who were free of diabetes and insulin resistance 
(IR) at baseline, were followed for approximately 2 years.29 A subset of children 
(n=1,042) wore an accelerometer and had to have at least 3 measurement days with a 
minimum of 8 hours of wear time per day. Time spent performing MVPA was identified 
and categorized into quartiles (Q1: ≤27 min/day; Q2: >27 to ≤38.7 min/day; Q3: >38.7 to 
≤54.6 min/day; Q4: >54.6 mins/day). The primary outcome was insulin resistance 
(HOMA-IR), which was taken in a fasting state. Compared to children performing the 
lowest level of MVPA (≤27 min/day), children engaging in levels of MVPA >38.7 
min/day had a reduction in the odds of developing insulin resistance: Q2: (OR=1.1; 95% 
CI: 0.7, 1.7); Q3: (OR=0.5; 95% CI: 0.3, 0.9); Q4: (OR=0.7; 95% CI: 0.5, 1.1).27 Models 
were adjusted for waist circumference z-score, sex, age, parental SES, sedentary time 
(hours per day of audio-visual media time), and diet (measured by fat consumption 
propensity score). The prevalence of IR in this population was 17.8%, which is 
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comparable to our prevalence of MetS (15.4%). In the IDEFICS cohort study, dietary 
propensity scores were developed based off of the parental food frequency questionnaire. 
Additionally, food consumed in the school or day care setting was excluded, making 
misclassification of dietary habits likely. 
An intervention study involving 349 obese 9–16 year olds in the Czech Republic 
reported strong effects of an intensive regimen of physical activity, along with diet, on 
metabolic risk factors.30 Over the course of one month, a 6 kg reduction in weight was 
observed, along with a 2.33 point reduction in BMI (kg/m2), a 5.6 cm reduction in waist 
circumference, a 3.1 mm Hg reduction in SBP, a 3.7 mm Hg reduction in DBP, a 0.69 
mmol/L reduction in LDL-C, a 0.19 mmol/L reduction in TG, and a 2.0 mIU/L reduction 
in insulin, among other outcomes.30 This study population was slightly younger than ours 
(mean age 13.7) and higher risk (all participants were obese). This intervention study 
demonstrates the physiologic benefits of physical activity on metabolic risk factors; 
however, the sizable effects achieved here cannot easily be generalized. This one-month 
lifestyle intervention program required children to participant in 5 units of aerobic and 
resistance training per day, with each unit lasting 50 minutes along with calorie 
restriction (5,000 kcal for children <10 years old and 7,000 kcal/day for children 10+).30 
This level of physical activity far exceeds daily recommendations in the US and is not 
sustainable. However, despite the lower levels of physical activity observed in our study, 
we were still able to detect a strong association between physical activity and metabolic 
risk factors. 
Given the relatively small number of studies available examining children and 
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adolescents, the following two studies in adults were assessed for comparison purposes. 
A prospective, observational, cohort study (The SUN Project) examined 10,145 Spanish 
university graduates free from MetS at baseline.31 Participants were followed for a 
minimum of 6 years, and the average age of participants was approximately 36 years old. 
Intensity of leisure time physical activity (LTPA) was categorized into quartiles. Self-
reported physical activity was measured in METs and the intensity of LTPA was 
calculated using the ratio of METs/week to total hours of LTPA per week, resulting in the 
average METs/hour of LTPA. MetS was defined according to the IDF criteria for adults.5 
This was nearly identical to our definition of MetS, except we followed the IDF 
guidelines for children, indicating the same HDL-C cut point for all children regardless of 
sex (<40 mg/dL; rather than <40 mg/dL for men and <50 mg/dL for women) and an 
examination of waist circumference percentile in addition to set values. 412 new cases of 
MetS were identified over the follow up period. Vigorous LTPA was associated with a 
reduction in risk of MetS compared to the reference group, light LTPA (OR=0.63; 95% 
CI: 0.44, 0.89). The model was adjusted for age, sex, smoking status, baseline BMI, total 
energy consumption, adherence to Mediterranean diet, following a special diet, snacking, 
sugar-sweetened beverage consumption, alcohol intake, French fry intake, fast-food 
consumption, education, computer use, TV watching, house chores, sleep, physical 
activity at work, prevalence of CVD and cancer, and total energy expenditure in LTPA 
per week.30 The effect observed in our study was slightly stronger in magnitude, although 
confidence intervals were slightly wider, likely due to our smaller sample size.  
Another prospective, observational cohort study, The Copenhagen City Heart 
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Study, of 3,992 men and women ages 21–98 and free of MetS at baseline, observed that 
15.4% of adults developed MetS at 10-year follow-up.32 Participants engaging in 
moderate/high LTPA had a 29% lower odds of developing MetS compared to their 
sedentary counterparts (OR=0.71; 95% CI: 0.50, 1.01). The model adjusted for alcohol 
consumption, smoking, income, duration of schooling, education, cohabitation, and age, 
but not diet. A sedentary pattern of activity was characterized by fewer than 2 hours per 
week of light PA (walking, slow biking, or gardening work). “Moderate + high” physical 
activity was defined as light PA >4 hours per week or 2–4 hours per week of more 
vigorous PA (sports that cause perspiration or exhaustion), or more than 4 hours per week 
of moderate PA or regular heavy exercise.32 MetS was defined using the latest criteria 
from the American Heart Association32; however, biomarker samples were not measured 
in a fasting state, which could result in bias and misclassification of the MetS outcome. 
Our study was able to adjust for diet, define MetS risk factors based on a fasting state, 
and we observed an effect of even larger magnitude in our adolescent sample.  
In addition to the collection of serum lipid levels in a fasting state, there were 
several other strengths of our study. OGTT was used to define elevated fasting plasma 
glucose and diabetes, rather than strictly relying on self-report of a previous diabetes 
mellitus diagnosis. The use of an objective diagnostic indicator alleviates concerns about 
underreporting and misclassification. Our study population was diverse, with 73% of 
participants who were non-white. Previous studies were limited by homogeneous, 
predominantly white study populations. Additionally, previous studies have had limited 
ability to evaluate the effects of sexual maturation on MetS. Although we were unable to 
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do so in boys, we were able to examine age at menarche in females. In this population, 
the risk of MetS among female adolescents who had an early menarche (<12 years old) 
was similar to risk among female adolescents who did not have an early menarche (≥12 
years old).  
This study was not without limitations. One of the most important limitations of 
this study, as is the case with all cross-sectional studies, is that exposure and outcome 
were assessed at the same time; therefore, we are unable to determine temporality of the 
association. Specifically, we observed a lower prevalence of MetS with increasing levels 
of physical activity. Because exposure and outcome were assessed at the same time, there 
is a possibility of reverse causation. The association could be due to the fact that 
participants were unable to engage in physical activity due to health concerns (diabetes, 
high blood pressure, obesity, etc.) related to metabolic syndrome. Another possibility is 
that overweight and obese children may be embarrassed to exercise because of their 
weight, associated stigma, or fear of being bullied. However, since several prospective, 
observational cohort studies reported similar results,29, 31–32 reverse causation is not a 
likely a likely explanation for our findings. Additionally, we stratified our analyses on 
extreme obesity (≥97th percentile vs. 85th to <97th percentile) to examine whether or not 
the ORs had the same inverse pattern in each stratum. Although the effect was stronger in 
the 85th to <97th percentile strata, the same inverse association pattern was observed in 
both groups. These results further refute the likelihood of reverse causality. 
Another limitation of our study is that there is lack of consensus on the definition 
of metabolic syndrome (MetS) in adults (Appendix 2) and, to date, the IDF is the only 
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group to attempt to define MetS in children and adolescents. The World Health 
Organization (WHO) developed adult criteria for metabolic syndrome first in 199834, 
which required the presence of glucose intolerance. The European Group for the Study of 
Insulin Resistance, or EGIR35, released criteria a year later. Those criteria were similar, 
putting the emphasis on insulin resistance and stating that MetS could not be defined in 
individuals with diabetes. Over the next several years, the National Cholesterol Education 
Program (NCEP ATPII) released several versions with the most recent not requiring the 
presence of any single risk factor, but simply three of the five: obesity, hyperglycemia, 
high TG, low HDL-C, high blood pressure.36 In 2007, the International Diabetes 
Federation (IDF) released criteria for MetS in adults and also included criteria for 
defining the condition in children.5 The IDF child/adolescent definition requires the 
presence of abdominal obesity and at least two other risk factors. Across all sets of 
criteria, there is little variability in the definition of high triglycerides and low HDL-C. 
However, there is large variability around defining obesity, blood pressure, 
hyperglycemia, and insulin resistance. The variability is most pronounced with respect to 
abdominal obesity. The NCEP ATPIII Guidelines define abdominal obesity in adults as a 
waist circumference >102 cm for men and >88 cm for women.36 The IDF Guidelines 
define abdominal obesity in adults as ≥ 94 cm for men and ≥ 80 cm for women.5 Given 
that we were using the adult abdominal obesity criteria for adolescents ages 16–19 in our 
study, we chose a more conservative approach and used the IDF guidelines for abdominal 
obesity. 
In this study, we decided to most closely follow the definition for MetS put forth 
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by the IDF, since this was the only criterion that included children and adolescents. 
However, we did not require abdominal obesity as a component, rather we required any 
three of the five criteria, which included: obesity, elevated fasting plasma glucose, high 
triglycerides, low HDL-C, and high blood pressure. We found several participants who 
did not meet the criteria for obesity, but were overweight and had three or four of the 
other MetS criteria, so we included them in our case definition. It did not seem 
appropriate to classify subjects who were overweight (but not obese) with three or four of 
the MetS criteria as metabolically healthy, or free from metabolic syndrome. Therefore, 
we chose to consider obesity like the other risk factors and, similar to the NCEP ATPIII 
criteria, required three of the five factors for a diagnosis of MetS. 
Physical activity was self-reported, which could lead to misclassification of 
exposure. It is possible that children with risk factors for MetS are more likely to over-
report their PA or that some participants with MetS risk factors are more likely to 
exercise because they are actively engaged in treatment for weight loss and metabolic 
risk reduction and, therefore, may be more accurate self-reporters than their less 
physically active peers; both scenarios would result in differential misclassification of 
exposure. Differential misclassification of exposure results in bias with an unpredictable 
direction. Because physical activity was self-reported, it is also possible that there is 
random measurement error, or information bias, which would result in a non-differential 
misclassification of exposure, generally biasing the odds ratio toward the null. 
Caution should be used when interpreting the results of our stratified models. 
Only 26 females were classified as having MetS and only 26 of the 159 subjects with 
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food insecurity were classified as having MetS, leading to less precise estimates.  
 In summary, in this study sample of overweight and obese 12–19 year olds, we 
found evidence of an inverse association between physical activity and metabolic 
syndrome. Specifically, increasing amounts of moderate-to-vigorous physical activity 
were associated with a lower odds of metabolic syndrome. In this racially diverse 
population, results were similar for males and females. Future studies should evaluate this 
association prospectively, and collect more detailed data on puberty and sexual 
maturation in both males and females to assess the potential influence of these factors on 
this relationship. 
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Table 2.1. Distribution of covariates by metabolic syndrome (MetS) for adolescents 12–19 
in NHANES 2007–2012 
 MetS (n=82) No MetS (n=451) 
Age (years) 16.4 ± 2.2 15.2 ± 2.2 
Sex   
    Male 56 (68.3%) 233 (51.7%) 
    Female 26 (31.7%) 218 (48.3%) 
Race/Ethnicity   
    White 20 (24.4%) 119 (26.4%) 
    Black 12 (14.6%) 137 (30.4%) 
    Hispanic 45 (54.9%) 162 (35.9%) 
    Other 5 (6.1%) 33 (7.3%) 
Smoking Status   
    Current smoker 16 (19.5%) 54 (12.0%) 
Food insecuritya 26 (31.7%) 124 (27.5%) 
Moderate-vigorous recreational physical 
activity (minutes per week) 
255.5 ± 325.6 358.7 ± 450.3 
Moderate-vigorous recreational physical 
activity 
  
   <30 minutes/week 30 (36.6%) 93 (20.6%) 
   30–179 minutes/week 15 (18.3%) 101 (22.4%) 
   180–479 minutes/week 16 (19.5%) 139 (30.8%) 
   480+ minutes/week 21 (25.6%) 118 (26.2%) 
Moderate physical activity 79.5 ± 131.7 132.2 ± 290.7 
Vigorous physical activity 176.1 ± 282.7 226.4 ± 326.5 
Poverty ratiob 1.7 ± 1.3 2.0 ± 1.5 
Fast food consumption   
   0 times/week 23 (28.1%) 152 (33.7%) 
   1–3 times/week 47 (57.3%) 236 (52.3%) 
   >3 times/week 12 (14.6%) 63 (14.0%) 
Energy (kcal)c 2169.5 ± 919.5 1869.4 ± 795.2 
Sugar (g)3 138.7 ± 86.4 111.9 ± 56.4 
Healthy Eating Index 2010 (HEI-2010) 
Total Score 
44.2 ± 13.2 46.9 ± 12.2 
BMI percentile 96.9 ± 3.3 94.0 ±4 .3 
Continuous Variables are presented as Mean ± SD and categorical variables are presented as N 
(%). 
aHead of household reported receiving food stamp benefit within the past 12 months. 
bMonthly family income divided by poverty guidelines specific to household size. A value <1 
indicates the household is living below the poverty level, a value of 1 indicates the house is living 
at the poverty level, and a value >1 indicates the household is living above the poverty level. 
Higher values indicate greater financial security. 
cAverage daily energy and sugar consumption were obtained from a 2-day dietary recall. If a 
subject was missing one day, a single day of data was used. 
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Table 2.2. Prevalence of individual metabolic risk factors by MetS in adolescents 12–19 in 
NHANES 2007–2012 
 MetS (n=82) 
n (%) 
No Metabolic Syndrome (n=451) 
n (%) 
Abdominal obesity   
   Yes 76 (93.8%) 276 (61.3%) 
   Waist circumference (cm) 106.9±12.9 92.9±12.7 
 
Low HDL-C   
   Yes 69 (85.2%) 87 (19.4%) 
    HDL-C (mg/dL) 37.2±6.4 49.4±9.6 
 
Diabetes or elevated fasting 
plasma glucose 
  
   Yes 54 (65.9%) 89 (19.7%) 
   Fasting glucose (mg/dL) 102.4±13.7 94.7±11.0 
 
High TG   
   Yes 51 (63.0%) 23 (5.1%) 
   Triglycerides (mg/dL) 165.2±81.1 83.0±41.5 
 
High blood pressure   
   Yes 19 (23.8%) 12 (2.7%) 
   SBP (mm Hg) 118.5±12.5 110.3±10.0 
   DBP (mm Hg) 63.1±12.6 58.0±12.1 
 
Metabolic risk factors*   
     0 --- 107 (23.7%) 
     1 --- 201 (44.6%) 
     2 --- 143 (31.7%) 
     3 62 (75.6%) --- 
     4 17 (20.7%) --- 
     5 3 (3.7%) --- 
*Subjects were classified based on non-missing metabolic risk factors. Subjects having 3 or 4 
metabolic risk factors were appropriately classified as MetS, even if they had missing values for 1 
or 2 risk factors. 
HDL-C=high density lipoprotein cholesterol; TG=triglycerides; SBP= Systolic Blood Pressure; 
DBP= Diastolic Blood Pressure 
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Table 2.3. Prevalence of demographics and individual metabolic risk factors by MVPA 
 Minutes per week of moderate-to-vigorous physical activity (MVPA) 
 <30 mins 
(n=123) 
n (%) 
30–179 mins 
(n=116) 
n (%) 
180–479 mins 
(n=155) 
n (%) 
480+ mins 
(n=139) 
n (%) 
DEMOGRAPHICS 
Age (years) 16.3 ± 2.2 14.9 ± 2.3 15.0 ± 2.2 15.5 ± 2.1 
Male 50 (40.7%) 56 (48.3%) 89 (57.4%) 94 (67.6%) 
Race/Ethnicity     
   White 29 (23.6%) 29 (25.0%) 37 (23.9%) 44 (31.7%) 
   Black 33 (26.8%) 26 (22.4%) 49 (31.6%) 41 (29.5%) 
   Hispanic 54 (43.9%) 49 (42.2%) 55 (35.5%) 49 (35.3%) 
   Other 7 (5.7%) 12 (10.3%) 14 (9.0%) 5 (3.6%) 
Current smoker 22 (17.9%) 15 (12.9%) 15 (9.7%) 18 (13.0%) 
Food insecuritya 36 (29.3%) 31 (26.7%) 48 (31.0%) 35 (25.2%) 
Poverty ratioc 1.7 ± 1.4 1.9 ± 1.5 1.8 ± 1.4 2.3 ± 1.5 
Fast food 
consumption 
    
   0 times/week 46 (37.4%) 40 (34.5%) 48 (31.0%) 41 (29.5%) 
   1–3 times/week 54 (43.9%) 62 (53.5%) 93 (6.0%) 74 (53.2%) 
   >3 times/week 23 (18.7%) 14 (12.1%) 14 (9.0%) 24 (17.3%) 
Energyc 1946 ± 821 1889 ± 825 1824 ± 796 2012 ± 844 
Sugarc 123 ± 74 106 ± 53 110 ± 55 124 ± 66 
HEI-2010 total score 46.2 ± 13.7 46.1 ± 1.9 46.3 ± 12.0 47.3 ± 11.1 
 
METABOLIC RISK FACTORS 
Abdominal obesity     
   Yes 102 (82.9%) 83 (72.2%) 89 (57.8%) 78 (56.1%) 
Low HDL-C     
   Yes 48 (39.3%) 36 (31.0%) 40 (25.8%) 32 (23.4%) 
Diabetes or elevated 
fasting plasma 
glucose 
    
   Yes 38 (30.9%) 33 (28.5%) 37 (23.9%) 35 (25.2%) 
High TG     
   Yes 22 (18.0%) 15 (12.9%) 19 (12.3%) 18 (13.1%) 
High blood pressure     
   Yes 9 (7.3%) 6 (5.3%) 7 (4.5%) 9 (6.5%) 
Metabolic risk 
factors* 
    
    0 12 (9.8%) 17 (14.7 %) 38 (24.5%) 40 (28.8%) 
    1 39 (31.7%) 47 (40.5%) 59 (38.1%) 56 (40.3%) 
    2 42 (34.2%) 37 (31.9%) 42 (27.1%) 24 (15.8%) 
    3 or more 30 (24.3%) 15 (12.9%) 16 (10.3%) 21 (15.1%) 
aHead of household reported receiving food stamp benefit within the past 12 months. 
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bMonthly family income divided by poverty guidelines specific to household size. A value <1 
indicates the household is living below the poverty level, a value of 1 indicates the house is living 
at the poverty level, and a value >1 indicates the household is living above the poverty level. 
Higher values indicate greater financial security. 
cAverage daily energy and sugar consumption were obtained from a 2-day dietary recall. If a 
subject was missing one day, a single day of data was used. 
*Subjects were classified based on non-missing metabolic risk factors. Subjects having 3 or 4 
metabolic risk factors were appropriately classified as MetS, even if they had missing values for 1 
or 2 risk factors.  
HDL-C= high density lipoprotein cholesterol; TG=triglycerides 
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Table 2.4. Component and total 2-day scores for participants with and without MetS, using 
the Healthy Eating Index 2010 (HEI-2010), adolescents 12–19, NHANES 2007–2012 
Component Max Points 
MetS (n=82) 
Mean (SD) 
No MetS (n=451) 
Mean (SD) 
Total vegetablesa 5 2.5 (1.4) 2.4 (1.4) 
Greens and beansa 5 1.1 (1.8) 0.9 (1.8) 
Total fruitb 5 2.0 (1.8) 2.3 (2.0) 
Whole fruitc 5 1.8 (2.0) 1.9 (2.2) 
Whole grains 10 1.8 (2.0) 2.0 (2.6) 
Total dairyd 10 6.1 (3.3) 6.3 (3.2) 
Total protein foodse 5 4.3 (1.1) 4.2 (1.2) 
Seafood and plant proteinse,f 5 1.4 (1.8) 1.4 (1.8) 
Fatty acidsg 10 4.2 (3.2) 4.6 (3.3) 
Refined grains 10 4.4 (3.3) 5.0 (3.4) 
Sodium 10 4.3 (3.1) 4.1 (3.2) 
Empty caloriesh 20 10.5 (6.2) 11.8 (5.4) 
HEI-2010 Total Score 100 44.2 (13.2) 46.9 (12.2) 
*For subjects with only 1 day of recall, the appropriate HEI-2010 SAS code was used to 
calculate HEI total score. 
aIncludes any beans and peas not counted as Total Protein Foods. 
bIncludes fruit juice. 
cIncludes all forms except juice. 
dIncludes all milk products such as fluid milk, yogurt, cheese, and fortified soy beverages. 
eBeans and peas are included here (and not with vegetables) when the Total Protein Foods 
standard is otherwise not met. 
fIncludes seafood, nuts, seeds, soy products (other than beverages) as well as beans and peas 
counted as Total Protein Foods. 
gRatio of poly- and monounsaturated fatty acids to saturated fatty acids. 
hCalories from solid fats, alcohol, and added sugars; threshold for counting alcohol is >13 
grams/1000kcal. 
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Table 2.5 The association between MVPA and MetS in overweight and obese 12–19 year 
olds in NHANES 2007–2012 (n=533) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Moderate-
vigorous 
recreational 
physical activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
Model 3c 
OR (95% CI) 
<30 mins/week 123 1.00 1.00 1.00 
30–179 mins/week 116 0.46 (0.23, 0.91) 0.53 (0.26, 1.07) 0.56 (0.27, 1.15) 
180–479 
mins/week 
155 0.36 (0.18, 0.69) 0.38 (0.19, 0.77) 0.41 (0.20, 0.82) 
480+ mins/week 139 0.55 (0.30, 1.03) 0.50 (0.26, 0.97) 0.51 (0.26, 0.99) 
aUnadjusted 
bAdjusted for age, sex 
c Adjusted for age, sex, and average grams sugar consumed 
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Table 2.6a The association between MVPA and MetS in overweight and obese 12–19 year 
old males in NHANES 2007–2012 (n=289) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Moderate–vigorous 
recreational 
physical activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
Model 3c 
OR (95% CI) 
<30 mins/week 50 1.00 (reference) 1.00 (reference) 1.00 (reference) 
30–179 mins/week 56 0.42 (0.17, 1.04) 0.48 (0.19, 1.21) 0.50 (0.20, 1.24) 
180–479 mins/week 89 0.25 (0.10, 0.59) 0.30 (0.12, 0.73) 0.30 (0.12, 0.75) 
480+ mins/week 94 0.49 (0.23, 1.06) 0.53 (0.24, 1.16) 0.54 (0.24, 1.18) 
Age   1.18 (1.03, 1.36) 1.18 (1.03, 1.36) 
Average daily 
grams sugar 
consumed 
 
  1.002 (0.997, 1.006) 
a Unadjusted 
b Adjusted for age 
c Adjusted for age and average grams sugar consumed 
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Table 2.6b The association between MVPA and MetS in overweight and obese 12–19 year 
old females in NHANES 2007–2012 (n=244) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Moderate–
vigorous 
recreational 
physical activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
Model 3c 
OR (95% CI) 
Model 4d 
OR (95% CI) 
<30 mins/week 73 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
30–179 mins/week 60 0.42 (0.14, 1.25) 0.61 (0.19, 1.90) 0.59 (0.19, 1.86) 0.68 (0.21, 2.20) 
180–479 
mins/week 
66 0.46 (0.17, 1.30) 0.61 (0.21, 1.76) 0.63 (0.22, 1.83) 0.73 (0.24, 2.21) 
480+ mins/week 45 0.22 (0.05, 1.00) 0.30 (0.06, 1.45) 0.32 (0.07, 1.53) 0.26 (0.05, 1.39) 
Age   1.26 (1.03, 1.55) 1.25 (1.02, 1.54) 1.21 (0.98, 1.49) 
Early menarche 
(< 12 years old) 
 
  0.76 (0.31, 1.84) 0.71 (0.28, 1.76) 
Average daily 
grams sugar 
consumed 
 
   1.01 (1.00, 1.02) 
a Unadjusted 
bAdjusted for age 
cAdjusted for age and early period 
dAdjusted for age, early period, and average daily grams of sugar consumed 
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Table 2.7a The association between MVPA and MetS in overweight and obese 12–19 year 
olds in NHANES 2007–2012: Food Insecure (received food stamps in past 12 months 
(n=150) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Moderate–vigorous 
recreational physical 
activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
Model 3c 
OR (95% CI) 
<30 mins/week 36 1.00 (reference) 1.00 (reference) 1.00 (reference) 
30–179 mins/week 31 0.14 (0.03, 0.68) 0.20 (0.04, 1.09) 0.27 (0.05, 1.49) 
180–479 mins/week 48 0.40 (0.14, 1.12) 0.48 (0.16, 1.44) 0.65 (0.21, 2.04) 
480+ mins/week 35 0.26 (0.07, 0.90) 0.31 (0.08, 1.19) 0.33 (0.08, 1.33) 
Age   1.23 (0.99, 1.54) 1.20 (0.96, 1.50) 
Male   1.33 (0.52, 3.38) 1.11 (0.42, 2.93) 
Average daily grams 
sugar consumed 
 
  1.01 (1.00, 1.01) 
a Unadjusted 
b Adjusted for age, sex 
c Adjusted for age, sex, and average grams sugar consumed 
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Table 2.7b The association between MVPA and MetS in overweight and obese 12–19 year 
olds in NHANES 2007–2012: Not Food Insecure (did not receive food stamps in past 12 
months (n=383) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Moderate–vigorous 
recreational 
physical activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
Model 3c 
OR (95% CI) 
<30 mins/week 87 1.00 (reference) 1.00 (reference) 1.00 (reference) 
30–179 mins/week 85 0.69 (0.32, 1.52) 0.73 (0.32, 1.66) 0.73 (0.32, 1.67) 
180–479 mins/week 107 0.31 (0.13, 0.75) 0.31 (0.12, 0.79) 0.31 (0.12, 0.79) 
480+ mins/week 104 0.75 (0.36, 1.56) 0.61 (0.28, 1.34) 0.61 (0.28, 1.32) 
Age   1.18 (1.03, 1.35) 1.18 (1.03, 1.35) 
Male   3.11 (1.56, 6.18) 2.97 (1.48, 5.96) 
Average daily grams 
sugar consumed 
 
  1.002 (0.997, 1.007) 
a Unadjusted 
bAdjusted for age, sex 
cAdjusted for age, sex, and average grams sugar consumed 
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Table 2.8a The association between Moderate Physical Activity and MetS in overweight 
and obese 12–19 year olds in NHANES 2007–2012 (n=533) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Moderate recreational physical 
activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
0 mins/week 281 1.00 1.00 
>0 to 150 mins/week 131 1.03 (0.58, 1.81) 1.30 (0.70, 2.30) 
>150 mins/week 121 0.88 (0.48, 1.61) 0.96 (0.51, 1.79) 
aUnadjusted 
bAdjusted for age, sex, and average grams sugar consumed 
 
Table 2.8b The association between Vigorous Physical Activity and MetS in overweight and 
obese 12–19 year olds in NHANES 2007–2012 (n=533) 
Odds Ratio (95% Confidence Interval) for Metabolic Syndrome (MetS) 
Vigorous recreational physical 
activity 
n 
Model 1a 
OR (95% CI) 
Model 2b 
OR (95% CI) 
0 mins/week 210 1.00 1.00 
>0 to 90 mins/week 52 0.52 (0.21, 1.30) 0.71 (0.27, 1.85) 
>90 to 315 mins/week 134 0.54 (0.29, 1.01) 0.58 (0.30, 1.12) 
>315 mins/week 137 0.61 (0.33, 1.10) 0.51 (0.27, 0.98) 
aUnadjusted 
bAdjusted for age, sex, and average grams sugar consumed 
  
  
39 
2.5 APPENDIX 
 
Appendix 2.1 Guidelines for Diagnosing MetS in Children5 
Age, 
years 
Obesity Triglycerides HDL-C 
Blood 
Pressure 
Fasting 
Glucose 
6 to 
<10 
WC ≥90th 
percentile 
Metabolic syndrome cannot be diagnosed in this age group. 
10 to 
<16 
WC ≥90th 
percentile 
TG ≥150 
mg/dL 
<40 mg/dL SBP ≥130 
mmHg 
DBP ≥85 
mmHg 
≥100 mg/dL or 
diagnosed T2D 
 
(If ≥100 mg/dL 
[or T2DM] 
OGTT 
recommended) 
16+ 
(same 
as 
adults) 
WC ≥94 
cm (males) 
WC ≥80 
cm 
(females) 
TG ≥150 
mg/dL or on 
treatment for 
lipid 
abnormalities 
<40 mg/dL 
(males) 
<50 mg/dL 
(females) or 
on treatment 
for lipid 
abnormalities 
SBP ≥130 
mmHg 
DBP ≥85 
mmHg or on 
treatment for 
hypertension 
≥100 mg/dL or 
diagnosed T2D 
WC=waist circumference 
SBP=systolic blood pressure 
DBP=diastolic blood pressure 
T2D=type II diabetes 
OGTT=oral glucose tolerance test 
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Appendix 2.2 Comparison of Criteria for Diagnosing MetS in Adults2, 5, 34–37 
 
WHO (1998)34 EGIR (1999)35 
NCEP ATP 
III (2005)36 
IDF (2007)5 
Required 
Glucose 
intolerance; IGT; 
DM 
Hyperinsulinemia 
(fasting plasma 
insulin ≥75th 
percentile) 
None Central obesity 
Criteria 
Glucose 
intolerance plus 
≥2 of the 
following 
Hyperinsulinemia  
plus ≥2 of the 
following 
≥ 3 of the 
following 5 
criteria 
Central obesity 
plus at least 2 
of the 
following 
Obesity 
Waist-to-hip ratio: 
>0.90 M, >0.85 F; 
BMI>30 kg/m2 
WC ≥94 cm M; 
≥90 cm F 
WC >102 cm 
M; >88 cm F 
(Required) 
WC≥94 cm M; 
WC≥80 cm F  
FPG/ 
Hyperglycemia/ 
IR 
Required 
FPG ≥110 mg/dL 
but nondiabetic 
FPG ≥100 
mg/dL or Rx 
FPG ≥100 
mg/dL or Rx 
TG ≥150 mg/dL ≥180 mg/dL or Rx 
≥150 mg/dL 
or Rx 
≥150 mg/dL or 
Rx 
HDL-C 
<35 mg/dL M; 
<39 mg/dL F 
<39 mg/dL or Rx 
<40 mg/dL M; 
<50 mg/dL F; 
or Rx 
<40 mg/dL M; 
<50 mg/dL F; 
or Rx 
Blood Pressure ≥160/90 mmHg 
≥ 140/90 mmHg 
or Rx 
SBP: ≥130 
mmHg and/or 
DBP: ≥85 
mmHg 
SBP: ≥130 
mmHg and/or 
DBP: ≥85 
mmHg 
Other 
Microalbuminuria
(urinary albumin 
excretion rate ≥20 
ug/min or 
albumin-to-
creatinine ratio 
≥20 mg/g) 
None None None 
M=males; F=females 
IGT=Impaired glucose intolerance; FPG= Fasting plasma glucose 
IR=Insulin resistance; TG=Triglycerides; HDL-C= High density lipoprotein 
cholesterol; DM=Diabetes mellitus; SBP=Systolic blood pressure; DBP=Diastolic 
blood pressure; WC=waist circumference 
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3. THE ASSOCIATION BETWEEN ENVIRONMENTAL TOBACCO SMOKE 
EXPOSURE AND CHILDHOOD OVERWEIGHT AND OBESITY 
 
 
3.1 INTRODUCTION 
Active smoking has been shown to be associated with lower BMI when 
comparing active smokers to non-smokers; however, research suggests that although 
BMI may be lower among smokers, an adverse fat distribution exists compared to non-
smokers.1 A prospective cohort study conducted in 22,059 Greek adults ages 25–84 
showed a lower BMI in smokers compared to non-smokers, but within smokers, BMI 
increased with increasing level of smoking. Additionally, among men, higher waist-to-
hip ratios were observed among smokers compared to non-smokers, indicative of 
abdominal obesity.1 
Research also shows an increased risk for higher BMI and metabolic syndrome 
(MetS) associated with passive smoking among adults.2 In a cross-sectional study of 389 
adults from 304 randomly selected Chinese households, exposure to environmental 
tobacco smoke (ETS) was associated with higher BMI and peripheral and central fat 
mass accumulation as well as an increased risk of MetS and hypertriglyceridemia.2 In this 
study, ETS was assessed via self-reported response to the following question: “Think 
about the past seven days (one week). On how many of those days were you in a room or 
vehicle (buses, cars, ships, trains) with someone who was smoking?” Answers were 
dichotomized ≤ 4 days vs. 5–7 days. The subjective measure of ETS in this study raises 
concern about misclassification of exposure and potentially biased results. 
  A similar association between BMI and passive smoking may also exist among 
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children and adolescents. In another prospective cohort study, researchers showed that 
children exposed to second hand smoke (SHS) had a greater increase in BMI from age 10 
to 18 compared to unexposed children; a dose-response relationship was observed for the 
number of smokers living in the household.3 This study, like the previous, was also 
limited by self-reported SHS exposure. Parents were asked whether or not there was a 
smoker living in the child’s home, if there ever was a smoker living in the home in the 
past, and the number of smoker(s) currently living in the child’s home, if any.  
The PIAMA (Prevention and Incidence of Asthma and Mite Allergy) birth cohort 
study, a prospective study examining 1,687 Dutch children born in 1996 and 1997, 
assessed predictors of childhood overweight at age 8. Smoking in the household was a 
strong independent positive predictor: OR=1.73 (95% CI: 1.47, 2.04).4 Other predictors 
in the model included father’s BMI, mother’s BMI, birthweight (kg), female sex, and 
hospital delivery (vs. at home delivery). The household smoke exposure was assessed via 
self-report and was dichotomized as smoking in the parental house (Y/N). The 
investigators did collect information on breastfeeding history and maternal vegetable 
consumption during pregnancy; however, these covariates were not included in the final 
model. No other information on dietary habits was collected, and information on physical 
activity was not collected. 
The Quebec Longitudinal Study of Child Development examined household 
smoke and adiposity measures at age ten.5 Parents were asked about smoking in the 
household at four time points throughout the child’s first 7 years. A ‘No’ response at all 
time points was defined as unexposed, a ‘Yes’ at one or more of the time points was 
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defined as transient exposure, and a ‘Yes’ at all four time points was defined as 
continuous exposure to ETS throughout childhood. In the fully adjusted multivariable 
logistic regression model adjusted for maternal smoking during pregnancy, maternal BMI 
(calculated from maternal report of height and weight at 17-month follow up appointment 
post-delivery), infant birthweight for gestational age, and maternal immigration status, 
transient household smoke exposure was associated with a 43% increase in odds of being 
overweight/obese at age 10 (OR=1.43 [95% CI: 1.12, 1.81]) and continuous household 
smoke exposure was associated with a 34% increase in odds of being overweight/obese at 
age 10 (OR=1.34 [95% CI: 0.90, 1.99]) compared to the unexposed group.5 Data were 
collected on maternal depressive symptoms (at 5-month follow-up), family income when 
the child was 5, maternal education, marital status, maternal age at birth of child, alcohol 
or drug use during pregnancy, child soft drink and snack intake (at 29-month follow-up), 
and child’s television watching habits (at 53-month follow-up). These potential 
confounders did not considerably alter the measures of effect and, therefore, were not 
included in the final model. Smoke exposure in this study was measured and classified 
based on parental self-report. Although one component of physical inactivity was 
captured in a proxy measure of TV viewing habits, physical activity was not measured 
and could potentially be a source of unmeasured confounding. 
Serum cotinine is a biomarker that provides an objective measure of exposure to 
environmental tobacco smoke. A major metabolite of nicotine, higher levels of serum 
cotinine indicate higher exposure to second-hand smoke. One study that used serum 
cotinine to define ETS was conducted in the NHANES III (survey years 1988–1994) 
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population where investigators examined the association between smoke exposure and 
metabolic syndrome (MetS) in 2,006 adolescents ages 12 to 19.6 Smoke exposure was 
divided into three categories: non-exposed, exposed to ETS, and active smoking. The 
non-exposed group was comprised of those with serum cotinine levels below the level of 
detection (<0.05 ng/mL) and no report of smokers living in the household. The second 
category was defined according to measurable serum cotinine levels (≤15 ng/mL and no 
report of smoking in the past 5 days), and the third category was comprised of 
adolescents who actively smoked (serum cotinine >15 ng/mL or self-report of smoking in 
the past 5 days).6 The non-exposed group accounted for 11.8% of the sample population, 
while the ETS-exposed group accounted for 67% and the active smoking group 
accounted for 21.2%. Results from a multivariable logistic regression analysis adjusted 
for sex, age, race/ethnicity, poverty status, region, and parental history of diabetes or 
heart attack showed a near five-fold increase in the risk of MetS for adolescents with ETS 
compare to the unexposed group (OR=4.7; 95% CI: 1.7, 12.9) and over a 6-fold increase 
in risk of MetS for adolescents who were active smokers (OR=6.1; 95% CI: 2.8, 13.4).6 
Individual components of MetS and their association with passive smoke exposure were 
also examined, with strong positive associations seen for high triglycerides, low HDL, 
and high waist circumference; a marginal association was also seen for overweight.6 
The majority of prior studies that examined the effect that ETS exposure has on 
childhood risk of overweight and obesity largely relied on parental self-report of an 
exposure that is difficult to quantify. Only one study measured exposure by serum 
cotinine levels. Further, we are not aware of any studies that have examined this 
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relationship using serum cotinine to define exposure in a young child. This study 
examined exposure to ETS and its relationship with overweight and obesity among 3–6 
year olds who participated in NHANES 2007–2012 using serum cotinine as the measure 
of environmental smoke exposure. 
 
3.2 METHODS 
3.2.1 Data Source 
The National Health and Nutrition Examination Survey (NHANES) data collected 
from 2007–20127 was used for this analysis. NHANES was designed to assess the health 
and nutritional status of adults and children in the United States. The survey is unique in 
that it collects interviews, physical exams, measured anthropometry, and biomarker data. 
NHANES began in the 1960s and in 1999 became a continuous program.8–13 NHANES 
draws a nationally representative sample of about 5,000 individuals each year.8  
3.2.2 Study Population and Design 
In this cross-sectional study combining data from 2007–2012 survey years, 2,563 
males and females ages 3–6 were examined and 1,565 had a laboratory value for serum 
cotinine. The analytical sample was restricted to normal, overweight, and obese 
participants. After removing children who were underweight (sex-specific BMI-for-age 
<5th percentile), 1,484 participants remained. Among them, 132 had at least one missing 
value for birthweight, breastfed as an infant, poverty ratio, and whether or not they had 
received food stamps in the past 12 months (an indicator of food insecurity) and were 
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excluded from the analysis. The remaining 1,352 children constituted the study 
population. 
3.2.3 Study Variables 
Outcome- Overweight  
The primary outcome of interest in this study was overweight defined by the CDC 
Growth Charts14 as a sex-specific BMI-for-age ≥85th percentile. The outcome was 
dichotomous indicating either overweight or not overweight.  
Exposure- Exposure to Environmental Tobacco Smoke (ETS) 
The primary exposure was environmental tobacco smoke (ETS) measured by 
serum cotinine levels. As described previously, serum cotinine is a major metabolite of 
nicotine and higher levels indicate higher exposure to ETS.15 While the half-life of 
nicotine is 2 to 3 hours, the half-life of cotinine is approximately 17 hours. Because of the 
longer half-life, levels of cotinine remain relatively stable throughout the day making a 
random cotinine measure a reasonable indicator of daily nicotine exposure.15 NHANES 
measured cotinine in the blood of participants ages 3 and older.10  
In this study, serum cotinine was examined both continuously and also 
categorically. Typically, non-smokers have serum cotinine measuring <1ng/mL; 
however, those with heavy second-hand smoke exposure can have serum cotinine levels 
ranging from 1–10 ng/mL. Active smokers generally have serum cotinine levels >10 
ng/mL that can climb upwards of 500 ng/mL.16 In NHANES, the lower level of detection 
in the laboratory was 0.015 ng/mL. There were instances in the NHANES data set where 
an individual’s result was below the lower level of detection; in these cases, the serum 
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cotinine value was recorded as 0.015 ng/mL divided by the square root of 2. In this 
analysis, serum cotinine was categorized as follows: 0 to <0.015 ng/mL (below level of 
detection), 0.015 ng/mL to <1 ng/mL (mild to moderate ETS exposure), and ≥1 ng/mL 
(heavy ETS exposure).  
Covariates 
Potential confounders including birthweight (grams), maternal smoking during 
pregnancy (Y/N), age, sex, race/ethnicity (Non-Hispanic White, Non-Hispanic Black, 
Hispanic, and Other), parental SES (measured by the family monthly poverty level index- 
ratio of monthly family income to the Department of Health and Human Services poverty 
guidelines specific to family size), parental education, breastfed (Y/N) and duration of 
breastfeeding defined by quartiles (0 days, 1–60 days, 61–243 days, and 244+ days) 
physical inactivity (hours spent watching TV or videos in the past 30 days plus minutes 
spent in sedentary activity on a typical day: categorized as more than 2 hours a day vs. 2 
hours or less), average daily caloric intake and average daily grams of sugar consumed 
(measured by a 2-day dietary recall), diet quality (measured by the Health Eating Index 
2010 (HEI-2010))17 and food insecurity (family received food stamps in the past 12 
months) were explored. Sugar intake (g) and total energy (kcal) were calculated by 
averaging the total sugar and total energy from each of the two 24-hour recall periods. 
Nutrient estimates were obtained using the USDA’s Food and Nutrient Database for 
Dietary Studies (FNDDS).18 Information on demographics, SES, diet, health and medical 
history was reported on the Sample Person Questionnaire and information for participants 
<16 was reported by an adult proxy.8 For children 6–11, diet interviews were conducted 
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with the child and the assistance of a proxy familiar with their dietary habits. For children 
under 6, the interviews for survey participants were conducted with a proxy most familiar 
with their dietary habits.11, 12 The Healthy Eating Index (HEI) measures overall diet 
quality. It consists of 12 components: (1) total fruit, (2) whole fruit, (3) total vegetables, 
(4) greens and beans, (5) whole grains, (6) dairy, (7) total protein foods, (8) seafood and 
plant proteins, (9) fatty acids, (10) refined grains, (11) sodium, and (12) empty calories. 
The scores of each component are summed together to create a total score (maximum 
possible value of 100), with higher values indicating an overall better diet quality. 
Validation of the HEI-2010 found overall adherence to dietary guidelines to be relatively 
poor in the NHANES population.19    
 
3.2.4 Data Analysis 
Descriptive analyses were conducted to examine the distribution and frequencies 
of the exposure and outcome variables as well as the covariates. Bivariate frequency 
tables between each potential confounder, outcome, and exposure were examined. Mean 
and standard deviations were calculated for continuous variables. Serum cotinine values 
were examined by overweight status (overweight vs. not overweight).  
Logistic regression was used to examine both the crude and adjusted measure of 
association between ETS and overweight. Potential confounders were added to the model 
one at a time and the relationship with the exposure and outcome was assessed. If the 
addition of the confounder appreciably altered the measure of association, the confounder 
was left in the model, otherwise, it was removed. When a final model was selected, the 
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confounders previously excluded were reexamined before deciding on the final model. 
Additionally, the subset of the population whose mothers did not smoke during 
pregnancy was examined in a subgroup analysis. This was done because of the difficulty 
in distinguishing the health effects of smoking during pregnancy from those occurring 
after birth, since women who smoked during pregnancy were perhaps likely to continue 
smoking post-delivery.20 
Stratified analyses were conducted to examine effect measure modification 
(EMM) by sex (male vs. female), race/ethnicity (Non-Hispanic White, Non-Hispanic 
Black, Hispanic, and Other), breastfed as an infant (yes/no), and poverty level (below 
poverty level vs. at or above poverty level). Stratified analyses were only conducted in 
the subset of the population of children born to mothers who did not smoke during 
pregnancy. 
The sample was analyzed using SAS statistical software (version 9.3, SAS 
Institute). NHANES survey weights were not taken into account given the specific 
subsample used. Additionally, the aim was to assess association and not prevalence; 
therefore, results are specific to this sample.21, 22 
 
3.3 RESULTS 
Among 1,352 3–6 year olds from NHANES 2007–2012 with a BMI ≥5th 
percentile for age and sex, an available serum cotinine lab value, and non-missing values 
for covariates, 399 (29.5%) children met the criteria for overweight (BMI ≥85th percentile 
for age and sex). Demographics are presented by overweight status in Table 3.1. 
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Overweight 3–6 year olds had serum cotinine levels, on average, 0.2 ng/mL greater than 
normal weight children. Age, dietary intake variables, and the distributions of sex, food 
insecurity, breastfeeding practice, and maternal smoking during pregnancy were similar 
between overweight and normal weight children in the study sample. 
Table 3.2 shows the distribution of demographic characteristics by serum cotinine 
category. The percentage of overweight subjects increased as serum cotinine level 
increased. The proportion of children from food insecure families increased as serum 
cotinine level increased. A similar pattern was observed such that the prevalence of 
maternal smoking during pregnancy and the proportion of children who spent more than 
2 hours per day engaged with TV/video games increased as serum cotinine increased. 
The proportion of children who were breastfed and the dietary quality score both 
decreased as serum cotinine level increased. 
Table 3.3 examines the dietary quality of subjects by overweight status. There 
was little variability in diet quality between overweight and normal weight 3–6 year olds 
as measured by the HEI-2010 based on two days of dietary recall data. However, overall 
diet quality for both groups was poor with overweight children scoring 53.1 and normal 
weight children scoring 53.5 for HEI-2010 total.  
Higher levels of serum cotinine were associated with an increased risk of 
overweight among 3 to 6-year-old children in NHANES III (Cochran-Armitage one-sided 
trend test, p=0.02). After adjusting for age, male sex, race/ethnicity, birthweight category 
(low: < 2500 g, normal: 2500 to < 4000g, high: ≥ 4000 g), poverty ratio, and breastfed as 
an infant (Y/N), the positive association remained. In the fully adjusted model with 
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unexposed as the referent group, the OR (95% CI) for overweight associated with a 
serum cotinine in the range of 0.015 ng/mL to < 1 ng/mL was 1.11 (0.79, 1.56); and for ≥ 
1 ng/mL, it was 1.59 (1.01, 2.52) (Table 3.4). There was little variation in energy intake, 
sugar intake, or diet quality between overweight and normal weight subjects and 
inclusion of the dietary variables in the model did not appreciably alter the effect 
estimates; therefore, none of the dietary variables were included in the final model. 
When examining the subset of the population who were born to mothers who did 
not smoke during pregnancy, the effect of ETS was slightly stronger (Table 3.5). In the 
fully adjusted model (adjusted for age, male sex, race/ethnicity, birthweight category, 
poverty ratio, and breastfed), the OR (95% CI) for serum cotinine measuring 0.015 
ng/mL to < 1 ng/mL was 1.18 (0.83, 1.66); and for ≥ 1 ng/mL was 1.49 (0.88, 2.53) 
compared to children who were unexposed to ETS. 
Models stratified by poverty level (Table 3.6) showed a stronger effect among 
those living below the poverty level. However, due to smaller cell sizes, confidence 
intervals widen and should be interpreted with caution. In the fully adjusted models for 
those living below the poverty level (adjusted for age, male sex, race/ethnicity, 
birthweight category, and breastfed), the OR (95% CI) for serum cotinine levels from 
0.015 ng/mL to < 1 ng/mL was 1.45 (0.71, 2.97); and for ≥ 1 ng/mL was 2.14 (0.90, 
5.09). The effect was much weaker for subjects living at or above the poverty level: the 
OR (95% CI) for serum cotinine levels of 0.015 ng/mL to < 1 ng/mL was 1.16 (0.79, 
1.72); and for ≥ 1 ng/mL was 1.26 (0.57, 2.76). 
Models stratified by whether or not the child was breastfed as an infant (Table 
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3.7) showed a stronger effect for children who were not breastfed as infants. In the fully 
adjusted model for children who were not breastfed as infants (adjusted for age, male sex, 
race/ethnicity, birthweight category, and poverty ratio) the OR (95% CI) for serum 
cotinine in the range 0.015 ng/mL to < 1 ng/mL was 1.69 (0.79, 3.63); and for ≥ 1 ng/mL 
was 2.36 (0.93, 6.00). In contrast, for children who were breastfed as infants, the OR 
(95% CI) for serum cotinine levels of 0.015 ng/mL to < 1 ng/mL was 1.07 (0.72, 1.57); 
and for ≥ 1 ng/mL was 1.35 (0.66, 2.74). 
Models stratified by sex (Table 3.8) showed a measurably stronger effect for 
females compared to males. In the fully adjusted model for females (adjusted for age, 
race/ethnicity, birthweight category, breastfed as an infant, and poverty ratio), the OR 
(95% CI) for serum cotinine levels of 0.015 ng/mL to < 1 ng/mL was 1.42 (0.84, 2.41); 
and for ≥ 1 ng/mL was 2.06 (0.95, 4.50). In the fully adjusted model for males, the 
association observed in the crude model was almost entirely explained away by adjusting 
for confounders. The OR (95% CI) for serum cotinine levels of 0.015 ng/mL to < 1 
ng/mL was 1.00 (0.63, 1.58); and for ≥ 1 ng/mL was 1.12 (0.54, 2.33). 
Models stratified by race/ethnicity (Table 3.9) yielded similar positive results 
across strata. Due to the small cell sizes, especially in the “other race” group, results 
should be interpreted cautiously. 
 
3.4 DISCUSSION 
In this diverse sample of normal weight, overweight and obese 3–6 year olds, we 
observed that exposure to environmental tobacco smoke has a positive association with 
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risk of overweight/obesity, with a dose-response effect observed indicating higher levels 
of ETS are associated with an increased risk of being overweight/obese. A modest 
association remained after adjustment for age, sex, race/ethnicity, birthweight, poverty 
level, and whether the child was breastfed as an infant. Further evaluation of a 
subpopulation of children born to mothers who did not smoke during pregnancy revealed 
similar results. The positive dose-response relationship was present among subgroups of 
children from families living both below and at or above the poverty level, children both 
breastfed and not breastfed as infants, females, and non-Hispanic whites, Hispanics, and 
“other race”, though in many cases confidence intervals were wider due to small 
numbers. 
Our findings are consistent with other studies that show a positive association 
between ETS and childhood overweight/obesity.3–5 We observed a positive-dose response 
relationship among females that was substantially stronger than that observed among 
males. Females with higher levels of ETS were more likely to be overweight, whereas 
there was little to no effect observed for males. This observation is consistent with a 
study of maternal smoking and fetal growth.23 The study was conducted in 856 
Scandinavian women, where 306 (35.7%) women were non-smokers, 242 (28.3%) were 
light smokers (1–9 cigarettes per day), and 308 (36.0%) were heavy smokers (≥ 10 
cigarettes per day). It was observed that maternal smoking affected birthweight 
parameters of male and female fetuses differently, with males affected more so than 
females. Male infants born to mothers who smoked heavily during pregnancy weighed, 
on average, 316 grams less than males born to mothers who did not smoke during 
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pregnancy. Females born to mothers who smoked heavily during pregnancy weighed, on 
average, 177 grams less than females born to mothers who did not smoke during 
pregnancy. Additionally, among boys, but not girls, a smaller head circumference was 
observed for male infants born to mothers who smoked heavily during pregnancy 
compared to mothers who did not smoke during pregnancy.23 Investigators concluded 
that tobacco is more detrimental to male compared to female fetuses.23 The biologic 
rationale for this conclusion is not well understood. It is worth noting that these authors 
examined gestational exposure whereas we examined early childhood exposure. 
However, given the similarities of the differences in effect on male and female offspring, 
a common biologic mechanism cannot be ruled out. 
In a prospective, observational cohort study of 2,055 Canadian children, 58.4% of 
children were never exposed to household smoking, 33.5% had transient exposure, and 
8.1% had continuous exposure.5 Exposure in that study was defined based on parental 
report of smokers in the household. Aside from the measurement error and bias 
associated with self-reported tobacco use, only examining the primary residence as a 
place of exposure fails to capture other possible exposure locations, including a relative’s 
house, at daycare, a friend’s house, etc. There is likely significant misclassification of 
exposure using these methods. Our study relied on serum cotinine, which objectively 
measures continuous daily smoke exposure more accurately. We were able to classify a 
truly non-exposed group as those who had serum cotinine levels below the lower level of 
detection by the lab. 18.2% of our population fell into this exposure category. We 
considered serum cotinine levels between 0.015 and <1 ng/mL to have low exposure to 
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environmental tobacco smoke, which accounted for 65.2% of our population. Lastly, 
those with serum cotinine levels ≥1 ng/mL were defined as a moderate-to-high level of 
exposure. An additional strength of this method is that we were able to assess all 
environmental smoke exposure, not just exposure in the primary residence. With our 
method, we observed an increase in risk of overweight for children with greater levels of 
tobacco exposure. Our effect was similar relative to the reference group (Table 3.5) as 
compared to the results of the Canadian study. However, unlike the Canadian study, we 
observed a dose-response effect.  
In the fully adjusted models in the Canadian study, investigators adjusted for 
gestational smoking, maternal BMI 17 months after birth, birthweight for gestational age, 
and maternal immigration status. Information on family income, maternal education, and 
child’s soft drink and snack intake over the last week was collected, but these variables 
were not retained in the final model.5 We found poverty ratio to have a substantial impact 
on the magnitude of the effect estimate and therefore, we included it in our final model. 
We also had information on whether the child was breastfed as an infant, which the 
Canadian study did not collect. We consider these enhancements a strength of our study 
lending validity to our results. 
  In the PIAMA (Prevention and Incidence of Asthma and Mite Allergy) birth 
cohort study, a prospective study of 1,687 Dutch children born between 1996 and 1997, 
investigators set out to identify predictors of overweight at age 8.4 A strong independent 
predictor of overweight at age 8 was the presences of smokers in the household 
(OR=1.73; 95% CI: 1.47, 2.04). Other predictors included in the final model were BMI of 
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father, BMI of mother, birthweight (kg), sex, and hospital as the birth site. Our positive 
association was not as strong as the effect seen here; however, the PIAMA study did not 
include maternal smoking during pregnancy in their final model, which we believe may 
have attenuated their observed effect. Furthermore, using serum cotinine to define 
exposure, rather than relying on parental report of smoking in the household yields a 
more reliable exposure assessment and reduces misclassification of average daily 
exposure, with the added advantage of not limiting the exposure assessment to the 
primary residence. 
The Southern California Children’s Health Study (CHS) examined the association 
between BMI and exposure to secondhand tobacco smoke (SHS) and air pollution among 
3,318 fourth graders.3 Children were followed for prospectively for 8 years. SHS was 
assessed by parents response to the following questions, “Does anyone living in this 
child’s home currently smoke cigarettes, cigars, or pipes on a daily basis INSIDE THE 
HOME?” or “In the past, has anyone living in this child’s home ever smoked cigarettes 
on a daily basis INSIDE THE HOME when the child was living there?”. If the parent 
reported the child was exposed currently, a follow up question was asked, “How many 
people smoke inside this child’s home on a daily basis?” with responses 0, 1, or 2 or 
more smokers. Children exposed to SHS had, on average, a BMI 1.23 kg/m2 greater than 
children not exposed to SHS (95% CI: 0.86, 1.61).3 This study, like many previous 
studies, classified the exposure based on parental report of smoking in the home. This 
method of characterizing exposure fails to capture any exposure outside of the primary 
residence, such as exposure at daycare, other family member’s homes, and the homes of 
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friends. Additionally, in this study, fully adjusted models controlled for ethnicity, sex, 
community, year of enrollment, and age, but not diet.  
There were several unique strengths of this study. Misclassification of exposure 
(ETS) is unlikely because a biologic marker of tobacco exposure was used (serum 
cotinine). Previous studies that have relied on parental self-report to estimate the child’s 
ETS exposure likely suffer from misclassification error and/or bias. Underreporting is 
common in studies where smoking status is self-reported. Additionally, using serum 
cotinine in our study, we are able to ascertain the average daily ETS exposure, not just 
exposure in the child’s residence. Children 3–6 years old may spend most of their time 
during the week in daycare or school, where the environment may differ from their 
household. Using serum cotinine measured in the blood, we are able to capture this. 
Misclassification of the outcome (overweight/obesity) is also unlikely given that height 
and weight were measured in NHANES. 
We did examine parental self-report of smoking in the household as the primary 
exposure, rather than serum cotinine, in the form of a sensitivity analysis. Despite a 
strong association between serum cotinine and number of smokers in the household, and 
serum cotinine and number of cigarettes smoked daily in the household, we show 
evidence that this method would lead to misclassification of exposure. Among children in 
the highest category of serum cotinine exposure (≥1 ng/ml), 38.0% were from households 
where the parent reported no smokers (of all tobacco types) living in the primary 
residence and 37.5% were from households where parents reported more than one pack 
of cigarettes smoked daily, on average. This observation not only encourages researchers 
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to question the reliability of self-reported ETS exposure, but provides further evidence 
that assessing exposure in the primary residence alone is not a valid measure of true ETS 
exposure among children. Additionally, we ran logistic regression models with a 
categorical variable for number of smokers in the household (0, 1, and 2+) rather than 
serum cotinine categories and we also ran logistic regression models with a categorical 
variable for average number of cigarettes smoked per day in the household (0, 1 to <20, 
20+). In both cases, these exposure variables failed to show the dose-response effect we 
observed using objectively measured exposure information. In our sensitivity analysis 
using self-reported exposure data, the strongest association was observed in the lowest 
exposure category relative to the reference group. This observation is consistent with the 
results observed in the Quebec Longitudinal Study of Child Development5 where a strong 
effect was observed for transient exposure from birth to age 7, but less so for continuous 
exposure from birth to age seven. 
Finally, we must consider the potentially confounding effects of maternal 
smoking while pregnant, distinguishing this behavior from current maternal and/or 
household smoking exposures. A strong, positive association between maternal smoking 
during pregnancy and childhood overweight/obesity has been established by numerous 
studies.24–27 Mothers who smoke during pregnancy are likely to continue smoking after 
delivery. NHANES collected data on whether the mother smoked during pregnancy. By 
restricting our analyses to the subgroup of children born to mothers who did not smoke 
during pregnancy, we were able minimize this potential source of confounding. 
One limitation of this study, as is the case with all cross-sectional studies, is that 
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exposure and disease were assessed at the same time; therefore, we are unable to 
determine temporality of the observed association. Our observations are strengthened by 
the findings from the three prospective cohort studies previously discussed that are in 
agreement with our results.3–5 
Another potential limitation in this line of research is the potential for residual 
confounding. Higher levels of smoking are observed among lower socioeconomic status 
(SES) groups and SES is a strong, well-established risk factor for overweight/obesity. We 
adjusted for markers of SES including race/ethnicity, birthweight (low, normal, high), 
ratio of family income to poverty (specific to family size), and whether the child was 
breastfed as an infant (oftentimes an indicator of increased income, parental education 
and/or other more general health-related behaviors). Adjusting for these factors 
attenuated, but did not completely explain the positive association between ETS and 
overweight/obesity. However, residual confounding cannot be ruled out.  
Caution should be exercised when interpreting the results of our stratified models. 
Due to the small numbers, confidence intervals around the point estimates are wider 
relative to the estimates for the entire population. 
While the biologic mechanism explaining the relationship between ETS and 
overweight/obesity is not fully understood, there are numerous hypotheses. Several 
studies have pointed to the inflammatory effects of tobacco smoke and the subsequent 
detrimental effects on lipid metabolism, insulin resistance, and the nervous system.3, 5, 28 
In summary, in this diverse sample of 3–6 year olds, we observed a positive 
association between ETS exposure and overweight/obesity. This study contributes to the 
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growing body of literature that ETS exposure has detrimental effects on weight and 
metabolic indicators with implications for the public health problem of childhood obesity. 
Future studies should evaluate this association prospectively in a larger population. 
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Table 3.1 Distribution of covariates by weight status among 3–6 year olds in NHANES 
2007–2012 
 Overweight  
BMI-for-age ≥85th 
percentile (n=399) 
Normal Weight  
5th≤ BMI-for-age <85th 
percentile (n=953) 
Age 4.7 ± 1.1 4.6 ± 1.1 
Sex   
  Male 209 (52.4%) 512 (53.7%) 
  Female 190 (47.6%) 441 (46.3%) 
Child’s BMI-for-age percentile 94.8 ± 4.6 50.5 ± 23.3 
Race/Ethnicity   
  Non-Hispanic White 102 (25.5%) 295 (31.0%) 
  Non-Hispanic Black 96 (24.1%) 236 (24.7%) 
  Hispanic 179 (44.9%) 327 (34.3%) 
  Other 22 (5.5%) 95 (10.0%) 
Breastfed as an infant 255 (63.9%) 645 (67.7%) 
Birthweight (grams) 3388.9 ± 614.8 3229.0 ± 596.9 
Birthweight category    
   Low (< 2500g) 27 (6.8%) 97 (10.2%) 
   Normal (2500 to < 4000 g) 324 (81.2%) 777 (81.5%) 
   High (≥ 4000 g) 48 (12.0%) 79 (8.3%) 
Watch >2 hours of TV/videos per day 130 (33.8%) 280 (30.4%) 
Energy (kcal)a 1702.1 ± 533.9 1679.7 ± 508.5 
Sugar (g)a   114.0 ± 43.7 112.8 ± 43.4 
Healthy Eating Index 2010 (HEI-2010) 
Total Score 
53.1 ± 11.7 53.5 ± 11.6 
Food insecurityb 177 (44.4%) 404 (42.4%) 
Mother smoked during pregnancy 52 (13.0%) 146 (15.3%) 
Poverty ratioc 1.5 ± 1.2 1.8 ± 1.4 
Serum cotinine (ng/mL) 0.8 ± 2.2 0.6 ± 1.8 
Serum cotinine category   
  <0.015 ng/mL (lower level of detection)  64 (16.0%) 182 (19.1%) 
  0.015 to <1 ng/mL 258 (64.7%) 624 (65.5%) 
  ≥1 ng/mL 77 (19.3%) 147 (15.4%) 
Continuous variables are presented as mean ± standard deviation and categorical variables are 
presented as N (%). 
aAverage daily energy and sugar consumption was obtained from a 2-day dietary recall. If a 
subject was missing one day, a single day of data was used. 
bHead of household reported receiving food stamp benefits within the past 12 months.   
cMonthly family income divided by poverty guidelines specific to household size. A value <1 
indicates the household is living below the poverty level, a value of 1 indicates living at the 
poverty level, and a value >1 indicates living above the poverty level. Higher values indicate 
greater financial security. 
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Table 3.2 Distribution of covariates by serum cotinine levels among 3–6 year olds in 
NHANES 2007–2012 
 Serum Cotinine 
< 0.015 ng/ml 
n= (246) 
Serum Cotinine 
≥0.015 and <1 ng/ml 
n= (826) 
Serum Cotinine 
≥1 ng/ml 
n= (224) 
Age 4.7 ± 1.1 4.6 ± 1.1 4.5 ± 1.1 
Male, n (%) 140 (56.9%) 465 (52.7%) 116 (51.8%) 
BMI percentile 59.8 ± 29.4 63.6 ± 28.3 67.3 ± 26.3 
Race/Ethnicity    
  Non-Hispanic White, n   (%) 71 (28.9%) 239 (27.1%) 87 (38.8%) 
  Non-Hispanic Black, n (%) 30 (12.2%) 209 (23.7%) 93 (41.5%) 
  Hispanic, n (%) 120 (48.8%) 363 (41.2%) 23 (10.3%) 
  Other, n (%) 25 (10.2%) 71 (8.1%) 21 (9.4%) 
Breastfed as an infant, n(%) 199 (80.9%) 606 (68.7%) 95 (42.4%) 
Birthweight (grams) 3294.8 ± 605.1 3300.0 ± 618.4 3162.1 ± 547.0 
Birthweight category, n(%)    
  Low birthweight (<2500 g) 24 (9.8%) 76 (8.6%) 24 (10.7%) 
  Normal birthweight  (2500 to 
<4000 grams) 
199 (80.9%) 711 (80.6%) 191 (85.3%) 
  High birthweight  
(≥4000 g) 
23 (9.4%) 95 (10.8%) 9 (4.0%) 
Watch more than 2 hours of 
TV/Videos per day, n (%) 
53 (22.3%) 260 (30.7%) 97 (43.7%) 
Energy (kcal)1 1629.4 ± 472.4 1684.5 ± 516.6 1754.8 ± 552.4 
Sugar (g)1 107.2 ± 36.8 113.6 ± 43.5 117.7 ±49.4 
Healthy Eating Index 2010 
(HEI-2010) Total Score 
56.8 ± 10.8 53.8 ± 11.5 47.7 ± 10.8 
Food insecurity2, n (%) 38 (15.5%) 379 (43.0%) 164 (73.2%) 
Mother smoked during 
pregnancy, n (%) 
3 (1.2%) 93 (10.5%) 102 (45.5%) 
Poverty ratio3, n (%) 2.6 ± 1.6 1.6 ± 1.3 1.0 ± 0.9 
Overweight, n (%) 64 (26.0%) 258 (29.3%) 77 (34.4%) 
Continuous variables are presented as mean ± standard deviation and categorical variables are 
presented as N (%). 
1Average daily energy and sugar consumption was obtained from a 2-day dietary recall. If a 
subject was missing one day, a single day of data was used. 
2Head of household reported receiving food stamp benefits within the past 12 months.   
3Monthly family income divided by poverty guidelines specific to household size. A value <1 
indicates the household is living below the poverty level, a value of 1 indicates living at the 
poverty level, and a value >1 indicates living above the poverty level. Higher values indicate 
greater financial security. 
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Table 3.3 Component and total 2-day scores for overweight and normal weight 
participants, using the Healthy Eating Index 2010 (HEI-2010), NHANES 2007–
2012 
Component Max Points 
Overweight (BMI-
for-age ≥ 85th 
percentile) 
Mean (SD) 
Normal Weight (5th-≤ 
BMI-for-age< 85th 
percentile) 
Mean (SD) 
Total vegetables1 5 2.1±1.3 2.1±1.3 
Greens and beans1 5 0.8±1.5 0.9±1.6 
Total fruit2 5 3.6±1.7 3.5±1.7 
Whole fruit3 5 3.3±2.0 3.3±2.0 
Whole grains 10 2.6±2.6 2.6±2.6 
Total dairy4 10 8.1±2.4 8.1±2.5 
Total protein foods5 5 3.9±1.3 3.8±1.2 
Seafood and plant proteins5,6 5 1.7±1.9 1.9±2.0 
Fatty acids7 10 3.6±3.0 3.5±2.9 
Refined grains 10 5.4±3.0 5.6±3.1 
Sodium 10 5.3±2.9 5.6±2.9 
Empty calories8 20 12.9±4.9 12.6±4.8 
HEI-2010 Total Score 100 53.1±11.7 53.5±11.6 
*For subjects with only 1 day of recall, the appropriate HEI-2010 SAS code was used to  
calculate HEI total score. 
1Includes any beans and peas not counted as Total Protein Foods. 
2Includes fruit juice. 
3Includes all forms except juice. 
4Includes all milk products such as fluid milk, yogurt, cheese, and fortified soy beverages. 
5Beans and peas are included here (and not with vegetables) when the Total Protein Foods 
standard is otherwise not met. 
6Includes seafood, nuts, seeds, soy products (other than beverages) as well as beans and peas 
counted as Total Protein Foods. 
7Ratio of poly- and monounsaturated fatty acids to saturated fatty acids. 
8Calories from solid fats, alcohol, and added sugars; threshold for counting alcohol is >13 
grams/1000kcal. 
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Table 3.4 Entire Population: The association between Environmental Tobacco Smoke 
(ETS) and overweight (N=1,352) 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Serum Cotinine  
   Below level of       
detection (<0.015 
ng/ml) 
246 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 882 1.18 (0.85, 1.62) 1.23 (0.89, 1.71) 1.11 (0.79, 1.56) 
   ≥1 ng/ml 224 1.49 (1.00, 2.21) 1.86 (1.22, 2.83) 1.59 (1.01, 2.52) 
Model 1 is unadjusted. 
Model 2 is adjusted for age, male sex, and race/ethnicity. 
Model 3 is adjusted for age, male sex, race/ethnicity (white, black, Hispanic, other), birthweight 
(low, normal, high), poverty ratio, and breastfed as an infant. 
 
Table 3.5 The association between Environmental Tobacco Smoke (ETS) and overweight 
among children born to mothers who did not smoke during pregnancy (n=1,154) 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Serum Cotinine  
   Below level of       
detection (<0.015 
ng/ml) 
243 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 789 1.26 (0.91, 1.74) 1.29 (0.93, 1.80) 1.18 (0.83, 1.66) 
   ≥1 ng/ml 122 1.56 (0.97, 2.49) 1.76 (1.07, 2.89) 1.49 (0.88, 2.53) 
Model 1 is unadjusted. 
Model 2 is adjusted for age, male sex, and race/ethnicity. 
Model 3 is adjusted for age, male sex, race/ethnicity (white, black, Hispanic, other), birthweight 
(low, normal, high), poverty ratio, and breastfed as an infant. 
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Table 3.6 The association between ETS and overweight among 3–6 year olds in NHANES 
2007–2012 stratified by poverty level* (n=432) 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Below the poverty level 432    
Serum Cotinine     
   Below level of       
detection (<0.015 ng/ml) 
46 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 304 1.32 (0.66, 2.68) 1.47 (0.72, 3.01) 1.45 (0.71, 2.97) 
   ≥1 ng/ml 82 1.72 (0.78, 3.81) 2.19 (0.93, 5.15) 2.14 (0.90, 5.09) 
 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
At or above the poverty 
level 
722  
  
Serum Cotinine     
   Below level of       
detection (<0.015 ng/ml) 
197 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 485 1.21 (0.83, 1.76) 1.25 (0.85, 1.83) 1.16 (0.79, 1.72) 
   ≥1 ng/ml 40 1.23 (0.58, 2.59) 1.38 (0.64, 2.99) 1.26 (0.57, 2.76) 
*Population where mothers did not smoke during pregnancy. 
Model 1 is unadjusted. 
Model 2 is adjusted for age, male sex, and race/ethnicity. 
Model 3 is adjusted for age, male sex, race/ethnicity (white, black, Hispanic, other), birthweight 
(low, normal, high), and breastfed as an infant. 
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Table 3.7 The association between ETS and overweight 3–6 year olds in NHANES 2007–
2012 stratified by infant feeding practice* 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Breastfed as infants 808    
Serum Cotinine     
   Below level of detection 
(<0.015 ng/ml) 
199 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 558 1.19 (0.82, 1.71) 1.19 (0.82, 1.74) 1.07 (0.72, 1.57) 
   ≥1 ng/ml 51 1.45 (0.75, 2.82) 1.61 (0.81, 3.19) 1.35 (0.66, 2.74) 
 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Not breastfed as infants 346    
Serum Cotinine     
Below level of  detection 
(<0.015 ng/ml) 
44 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 231 1.39 (0.68, 2.84) 1.59 (0.76, 3.32) 1.69 (0.79, 3.63) 
   ≥1 ng/ml 71 1.54 (0.68, 3.50) 2.09 (0.87, 5.03) 2.36 (0.93, 6.00) 
*Population where mothers did not smoke during pregnancy. 
Model 1 is unadjusted. 
Model 2 is adjusted for age, male sex, and race/ethnicity. 
Model 3 is adjusted for age, male sex, race/ethnicity (white, black, Hispanic, other), birthweight 
(low, normal, high), and poverty ratio. 
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Table 3.8 The association between ETS and overweight for 3–6 year olds in NHANES 
2007–2012 stratified by sex* 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Males 614    
Serum Cotinine     
   Below level of detection 
(<0.015 ng/ml) 
139 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 412 1.11 (0.72, 1.70) 1.08 (0.70, 1.68) 1.00 (0.63, 1.58) 
   ≥1 ng/ml 63 1.24 (0.65, 2.36) 1.32 (0.66, 2.64) 1.12 (0.54, 2.33) 
 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Females 540    
Serum Cotinine     
Below level of detection 
(<0.015 ng/ml) 
104 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 377 1.48 (0.90, 2.43) 1.57 (0.94, 2.61) 1.42 (0.84, 2.41) 
   ≥1 ng/ml 59 2.02 (1.01, 4.02) 2.39 (1.16, 4.93) 2.06 (0.95, 4.50) 
*Population where mothers did not smoke during pregnancy. 
Model 1 is unadjusted. 
Model 2 is adjusted for age, and race/ethnicity. 
Model 3 is adjusted for age, race/ethnicity (white, black, Hispanic, other), birthweight (low, 
normal, high), breastfed as an infant, and poverty ratio. 
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Table 3.9 The association between ETS and overweight among 3–6 year olds in NHANES 
2007–2012 stratified by race/ethnicity* 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Non-Hispanic Whites 397    
Serum Cotinine     
   Below level of       
detection (<0.015 
ng/ml) 
71 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 239 1.28 (0.64, 2.57) 1.21 (0.60, 2.44) 1.11 (0.52, 2.34) 
   ≥1 ng/ml 87 1.84 (0.71, 4.79) 1.74 (0.66, 4.57) 1.65 (0.55, 4.94) 
 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Hispanics 506    
Serum Cotinine     
   Below level of       
detection (<0.015 
ng/ml) 
120 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 363 1.02 (0.66, 1.58) 1.07 (0.69, 1.67) 1.06 (0.68, 1.66) 
   ≥1 ng/ml 23 2.27 (0.87, 5.91) 2.40 (0.92, 6.31) 2.30 (0.87, 6.13) 
 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Non-Hispanic Blacks 322    
Serum Cotinine     
   Below level of       
detection (<0.015 
ng/ml) 
30 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 209 1.82 (0.71, 4.68) 1.77 (0.68, 4.57) 1.46 (0.53, 4.00) 
   ≥1 ng/ml 89 1.78 (0.63, 5.02) 1.71 (0.60, 4.86) 1.28 (0.40, 4.07) 
 
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Other 117    
Serum Cotinine     
Below level of       
detection (<0.015 
ng/ml) 
25 1.00 (Reference) 1.00 (Reference) 1.00 (Reference) 
   0.015 to <1 ng/ml 71 3.43 (0.72, 16.36) 3.58 (0.74, 17.30) 2.40 (0.44, 13.13) 
   ≥1 ng/ml 21 11.50 (1.01, 131.28) 13.20 (1.10, 158.29) 8.13 (0.53, 124.86) 
*Population where mothers did not smoke during pregnancy. 
Model 1 is unadjusted. 
Model 2 is adjusted for age, and race/ethnicity. 
Model 3 is adjusted for age, male sex, birthweight (low, normal, high), breastfed as an infant, 
and poverty ratio. 
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4. THE ASSOCIATION BETWEEN MATERNAL EXPOSURE TO 
ANTIBIOTICS DURING PREGNANCY AND SMALL FOR GESTATIONAL 
AGE 
 
4.1 INTRODUCTION 
Antibiotics are one of the most frequently used drugs during pregnancy. The most 
common indications for use include respiratory infection, urinary tract infection, 
vaginal/yeast infection, and skin infection.1 However, recent research suggests that 
antibiotic use during pregnancy may alter the microbial diversity of the gastrointestinal 
(GI) tract not only of the mother but also of the baby.2,3 Altered gut microbiota in utero 
and infancy may increase the susceptibility of these infants to obesity later in childhood.4 
This is supported by several studies that showed differences in fecal microbiota in obese 
compared to lean and normal weight individuals.4–7 Kalliomaki, et al. also reported that 
40% of overweight children and 13% of normal-weight children were exposed to 
antibiotics in the first 6 months of life, although their sample size was small (N=49).4 
Recent studies that examined antibiotic use in pregnancy suggested an association with 
infant birthweight. However, studies on maternal antibiotic use during pregnancy and 
infant birthweight have yielded conflicting results and comparisons across studies are 
restricted by inconsistencies in defining the outcome, different methods and timing of 
exposure assessment, and inability to explore various characteristics of exposure 
including duration of use, trimester of use, class of antibiotic, and indication for use.  
Two studies have reported higher birthweight among infants born to mothers who 
used antibiotics during pregnancy.8, 9 In a study of 38,151 women who gave birth to 
infants without congenital abnormalities, 6,554 (17.2%) of women self-reported 
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antibiotic use during pregnancy, with 5,518 (84.2%) of these women reporting penicillin 
class antibiotics.8  Women who reported antibiotic use during pregnancy gave birth to 
infants who were, on average, 36 grams heavier than infants born to mothers who did not 
report antibiotic use (3311 g (SD=510) vs. 3275 g (SD=521)). However, the objectives of 
this study were to evaluate the frequency of, and indications for, antibiotic use during 
pregnancy. Intrauterine infection is associated with preterm delivery, which is strongly 
correlated with birthweight. Thus, the association with higher birthweights might be due 
to preventing preterm delivery.10 
Another study of primiparous women with live births or still births after 28 weeks 
gestation in North Jutland, Denmark, reported that mothers who redeemed any 
prescription for amoxicillin during pregnancy gave birth to infants who weighed, on 
average, 57 grams more at birth than infants born to mothers who did not redeem any 
prescriptions in the exposure period ranging from 3 months prior to pregnancy through to 
the end of pregnancy.9 Models were adjusted for maternal age, gestational age, and 
maternal smoking. When restricting to full term births, amoxicillin use during pregnancy 
was also protective against low birthweight (OR=0.63; 95% CI: 0.26, 1.53). 
Other studies have observed an association between antibiotic use during 
pregnancy and lower birthweight.2,11 In the Newborn Epigenetic STudy (NEST), a 
prospective cohort study of women and children, infants born to mothers who used 
antibiotics during pregnancy, on average, weighed 133 grams (se=50.70) less than infants 
born to mothers who did not take antibiotics during pregnancy.2 Similarly, in a study of 
2,128 pregnant women from the pre-birth Project Viva cohort, antibiotic use during 
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pregnancy was associated with lower BW/GA-z scores; BW/GA-z scores were one-ninth 
of a standard deviation lower for infants exposed to antibiotics in utero compared to 
unexposed infants (β= -0.11; 95% CI: -0.20, -0.01). The NEST study was unable to 
examine duration of antibiotic use and both studies were unable to rule out confounding 
by indication.2, 11 It is possible that the lower observed birthweight is due, in part, to the 
indication for which the antibiotics were prescribed. 
Further research on the relationship between maternal antibiotic use during 
pregnancy and birthweight is needed. Only a limited number of studies have been 
conducted on this topic, and the results have been conflicting. One possible reason for 
these discrepant results could be confounding by indication. In other words, the 
relationships previously observed between maternal antibiotic use and birthweight may 
actually be driven by the indication for which the antibiotic was prescribed. Additionally, 
characteristics of maternal antibiotic use during pregnancy including dose, duration, and 
timing of use are understudied. Understanding how maternal antibiotic use during 
pregnancy is related to birthweight can have important public health implications 
including prevention of low (and possibly high) birthweight and subsequent childhood 
obesity as well as targeted intervention strategies. 
 
4.2 METHODS 
4.2.1 Data Source 
The study population consisted of control participants from the Slone 
Epidemiology Center’s Birth Defects Study (BDS).12 The BDS interviewed mothers of 
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infants born with major structural birth defects ascertained from birth and tertiary care 
hospitals in Boston, Philadelphia, Toronto, Iowa, Tennessee, New York, and San Diego. 
For the present analysis, mothers of control subjects who were interviewed between 1998 
and 2015 were included. They were ascertained from birth hospitals where cases were 
ascertained, except in Massachusetts where a random sample of births were identified 
from vital records information provided by the Massachusetts Department of Public 
Health (MDPH).13 All subjects were identified within five months of delivery and all 
mothers were interviewed within six months of delivery. 
In the Birth Defects Study, data were available on characteristics of maternal 
antibiotic use during pregnancy including timing, dose, duration, indication, and class of 
antibiotic used. Mothers were interviewed by study nurses using standardized 
questionnaires with specific prompts for antibiotics and infections. Computer assisted 
telephone interviews were conducted by trained nurses. In addition to medication and 
vitamin use, detailed questions were also asked about demographic, reproductive, and 
behavioral factors.12 
 
4.2.2 Study Population and Design 
Included in this retrospective cohort analysis are 11,421 control subjects from the 
Birth Defects Study. We restricted our analysis to 11,077 singleton births (97% of births) 
and excluded another 21 subjects with missing values for infant birthweight. A complete 
case analysis was conducted, removing subjects with missing information on maternal 
variables: age, race, smoking during pregnancy, education, height, and weight. A final 
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sample size of 10,647 subjects was used for this analysis. Among them, approximately 
2,677 (25.1%) reported maternal antibiotic use during pregnancy.  
 
4.2.3 Study Variables 
Outcome- Small for Gestational Age (SGA) 
The primary outcome was small for gestational age (SGA). Infant birthweight was 
self-reported by the mother at the time of interview. The gestational age (in weeks) was 
calculated by subtracting the date of the last menstrual period (LMP) from the delivery 
date and dividing by 7. Infants with birthweight-for-gestational-age z-scores below the 
10th percentile as defined according to the growth curves developed by Oken, et al. were 
classified as SGA.14 These growth curves used data from the United States Natality 
datasets and analyzed nearly 7 million infants (6,690,717) born at 22–44 weeks gestation 
between 1999 and 2000 to US residents. We chose to use SGA as our outcome rather 
than birthweight with adjustment for gestational age for two reasons: (1) adjusting for 
gestational age assumes a strict linear relationship between birthweight and gestational 
age, which is not necessarily the case, and 2) even though gestational age is highly 
correlated with birthweight, it is in the causal pathway between antibiotic use and 
birthweight (or a consequence of birthweight) and therefore adjustment can create biased 
estimates.14 We also examined birthweight adjusted for gestational age z-score (BW/GA-
z) as a continuous measure. 
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Exposure-Maternal Antibiotic Use during Pregnancy 
Women were asked if they had taken any drugs for a list of illnesses, including 
respiratory, genitourinary and other infections, and if they had taken any of a list of 
specific medications [Appendix 1]. Women who couldn’t remember the exact name of 
the antibiotic were read a list to aid recall [Appendix 2]. For each reported medication, 
women were asked to state the drug name, start and stop dates, and reason for taking it. 
The primary exposure was maternal antibiotic use during pregnancy, defined as a 
dichotomous variable (yes/no), regardless of the number of uses. Other characteristics of 
antibiotic exposure that were considered included trimester of use, class of antibiotic, 
duration of use (0 days, 1–6 days, 7–10 days, 11+ days), and indication for use. 
Antibiotic class was determined by a research pharmacist based on the reported name of 
the product and American Hospital Formulary (AHFS)15 as shown in Appendix 3. 
Classes with at least 90 reports in our dataset were examined, including penicillins, 
macrolides, cephalosporins, and miscellaneous antibacterials. Additionally, we examined 
as a group the large number of antibiotics with class not otherwise specified (Antibiotics-
NOS). A complete list of indications for antibiotic use is provided in Appendix 4. The 
most common indications for use in the BDS control cohort were respiratory infections 
and genitourinary infections1; therefore, indications for use were classified into three 
categories: (1) respiratory infections, (2) genitourinary infections, and (3) other. Duration 
of use was recorded as total time in days the drug was taken over the course of 
pregnancy, and was examined as a categorical variable with four categories: 0 days, 1–6 
days, 7–10 days, and 11+ days. These categories were confirmed by examining tertiles of 
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duration.  
Covariates 
Potential confounders included maternal age, maternal pre-pregnancy BMI, 
maternal smoking status during pregnancy (yes/no), highest level of parental education 
(less than high school, high school, some college, college plus), and mother’s 
race/ethnicity. Maternal age, pre-pregnancy weight and weight at delivery, smoking 
status during pregnancy, race/ethnicity, and parental education were all self-reported by 
the mother during the interview. 
 
4.2.4 Data Analysis 
These data were analyzed using SAS statistical software (version 9.3, SAS 
Institute). Distributions of covariates were examined by SGA status and antibiotic 
exposure status. Bivariate frequency tables between each potential confounder, outcome, 
and exposure were examined. Means and standard deviations were calculated for 
continuous variables.  
Multivariable logistic regression was used to examine the adjusted measure of 
association between maternal antibiotic use during pregnancy and SGA. Multivariable 
linear regression was used to examine the adjusted measure of association between 
BW/GA-z and maternal antibiotic use during pregnancy. Potential confounders were 
added to the model one at a time and the relationship with the exposure and outcome was 
assessed. If the addition of the confounder altered the measure of association by at least 
3%, the confounder was left in the model, if not, it was removed. When a final model was 
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selected, the confounders previously excluded were reexamined before deciding on the 
final model. Because maternal smoking is a known risk factor for decreased birthweight, 
it was retained in all models. Models stratified by maternal smoking during pregnancy 
and infant sex were examined to explore whether there was evidence of effect measure 
modification (EMM) by smoking status or infant sex. 
The association between SGA and trimester of antibiotic use was also examined. 
Indication variables for each trimester were included in the model indicating whether the 
infant was exposed to antibiotics during that trimester. In a sensitivity analysis, we 
explored these same models restricted to infants only exposed to antibiotics during a 
single trimester to better isolate trimester-specific effects. 
Duration of antibiotic use (in days) was summed across the entire pregnancy for 
women with multiple episodes of use. Duration was categorized based on approximate 
tertiles of the data (1–6 days, 7–10 days, and 11+ days; with 0 days as the reference 
group). 
Antibiotic class was also explored. First, we examined the association between 
SGA and penicillin class antibiotics during pregnancy regardless of whether they 
reported use of other antibiotic classes. If they used antibiotics, but not penicillin class, 
they were classified as a ‘Non-penicillin user’. The reference group consisted of mothers 
who did not report any antibiotic use during pregnancy. This process was repeated for 
cephalosporin use, macrolide use, antibiotic NOS, and miscellaneous antibacterial use. 
We also examined the association between indication for antibiotic use and SGA 
among mothers who reported antibiotic use during pregnancy. Indication was classified 
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as respiratory infection if the subject reported respiratory infection at all during 
pregnancy; otherwise, they were classified as ‘Other Infection’. This same process was 
repeated for genitourinary infections. Additionally, we explored indication in all subjects 
using mothers who did not report any antibiotic use during pregnancy as the reference 
group. 
 
4.3 RESULTS 
Among the 10,647 singleton births with available information on maternal 
antibiotic use during pregnancy and non-missing values for covariates, 891 (8.4%) were 
classified as SGA. The distributions of demographic variables are presented by SGA 
status in Table 4.1. A slightly smaller percentage of SGA infants were exposed to 
antibiotics during pregnancy compared to non-SGA infants (23.3% vs. 25.3%). Mothers 
of SGA infants were younger (mean age: 27.5 vs. 29.3 years), gained less weight during 
pregnancy (29.1 lbs. vs. 33.1 lbs.), were more likely to be non-white (non-white: 49.6% 
vs. 28.6%), less likely to be college educated (college or more: 42.8% vs. 59.1%), more 
likely to have smoked during pregnancy (12.9% vs. 6.5%), and less likely to be 
overweight/obese (28.4% vs. 34.7%) prior to pregnancy. Gestational age and infant sex 
were similar across SGA status. 
 Table 4.2 shows the distributions of covariates by exposure status. More than one 
in four mothers (n=2,677 (25.1%)) took antibiotics during pregnancy. Infants born to 
mothers who took antibiotics during pregnancy were less likely to be SGA (7.8% vs. 
8.6%); more likely to be female (52.4% vs. 50.1%), born preterm (6.8% vs. 6.0%), born 
to a smoker (9.4% vs. 6.3%), born to a mother who was obese prior to pregnancy (15.9% 
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vs. 12.7%); and less likely to be born to a college educated mother or father (53.9% vs. 
59.1%). Gestational age, maternal age, maternal weight gain during pregnancy, and 
maternal race/ethnicity were similar across exposure categories. Birthweight was also 
similar among infants born to mothers who took antibiotics during pregnancy and those 
who did not (3398 g vs. 3407 g). 
 Characteristics of antibiotic use during pregnancy are examined in Table 4.3. Of 
the 2,677 (25.1%) of mothers who took antibiotics during pregnancy, 2,044 (76.4%) had 
a single exposure period to antibiotics during pregnancy and 633 (23.6%) had 2 or more 
exposure periods over the course of pregnancy. There were 496 subjects with uncertain 
exposure periods and, therefore, not classified under any trimester. Of the 2,181 subjects 
who were able to recall the exposure period, a total of 1,074 (49%) indicated antibiotic 
use during the first, 669 (31%) in the second and 685 (31%) in the third trimester. A total 
of 56 subjects reported antibiotic use during pregnancy but had missing values for 
duration. Median duration of use was 8 days. Of the 2,621 reports for duration, 734 
(28.0%) were 1–6 days, 1,130 (43.1%) were 7–10 days, and 757 (28.9%) were >10 days. 
With respect to antibiotic type, nearly half (47.9%) of reports were classified as antibiotic 
NOS (not otherwise specified); the mother was unable to recall the type of antibiotic she 
took. Penicillin was the most common class of antibiotics taken among women who 
could reliably report drug type (25.6% of reports), followed by macrolides (15.3% of 
reports), miscellaneous antibacterials (3.0% of reports), cephalosporins (2.6% of reports), 
and lastly, other antibiotic (5.6%). The most common indication for use was respiratory 
infections (43.0% of reports), followed by genitourinary infections (37.5% of reports), 
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and “other infections” (19.5% of reports). 
 After adjusting for maternal smoking during pregnancy and parental education, 
any antibiotic use during gestation was associated with a slightly lower risk of SGA 
(OR=0.86; 95% CI: 0.73, 1.01) (Table 4.4). Models stratified by maternal smoking 
during pregnancy did not reveal evidence of effect measure modification (smokers: 
OR=0.81, 95% CI: 0.53, 1.25; non-smokers: OR=0.86, 95% CI: 0.72, 1.03) (Table 4.5). 
Models stratified by infant sex revealed nearly identical associations for female and male 
infants (females: OR=0.87, 95% CI: 0.69, 1.09; males: OR=0.85, 95% CI: 0.67, 1.07) 
(Table 4.6).  
 As a sensitivity analysis, we explored models with birthweight in grams as a 
continuous outcome adjusted for gestational age. The fully adjusted model indicated 
infants exposed to antibiotics during gestation weighed, on average, 12.27 g (95% CI: -
6.99, 31.53) more at birth compared to unexposed infants (Table 4.7). Fully adjusted 
models stratified by preterm status (<37 weeks vs. ≥ 37 weeks) indicated a negative 
association for preterm infants (β= -6.46 g, 95% CI: -89.84, 76.92) and a positive 
association for full term infants (β=14.44 g, 95% CI: -5.23, 34.12), but the magnitude of 
these associations were small and the confidence intervals were wide and therefore, 
should be interpreted with caution (Table 4.7). 
 Fully adjusted multivariable regression models examining the association between 
maternal antibiotic use during pregnancy and the continuous measure, BW/GA-z, 
indicated little association (β= 0.03; 95% CI: -0.01, 0.07) (Table 4.8a). Models stratified 
by maternal smoking during pregnancy also indicated no association; however, the 
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stratum-specific coefficients went in opposite directions (smoker: β= -0.02; 95% CI: -
0.17, 0.12; non-smoker: β= 0.03; 95% CI: -0.01, 0.07) (Table 4.8b). 
 Fully adjusted models examining timing of antibiotic use suggested virtually no 
association between antibiotic use during the first or second trimester and SGA (first 
trimester: OR=0.93, 95% CI: 0.74, 1.17; second trimester: (OR=1.01, 95% CI: 0.76, 
1.33). Antibiotic use during the third trimester was associated with a reduced risk of 
SGA: (OR= 0.82, 95% CI: 0.61, 1.11) (Table 4.9a). Sensitivity analysis restricted to 
single trimester users revealed nearly identical results for the first and second trimesters 
(OR=0.92, 95% CI: 0.71, 1.19; second trimester: OR=0.98, 95% CI: 0.71, 1.34). The 
reduction in risk of SGA was more notable for third trimester users when restricted to 
single trimester users (OR=0.73, 95% CI: 0.51, 1.04) (Table 4.9b). 
 Models examining the association of duration of antibiotic use on SGA did not 
show a dose-response effect; there was no increase in the protective effect with 
increasing duration of use. In fact, the largest protective effect was observed among the 
shortest duration users relative to non-users (OR=0.70; 95% CI: 0.52, 0.96) (Table 4.10). 
Analysis exploring class of antibiotic revealed no difference in risk of SGA for penicillin 
class users compared to non-antibiotic users during pregnancy (Table 4.11a). Macrolide 
users had a reduction in risk (OR=0.65; 95% CI: 0.42, 1.01) compared to non-users; 
cephalosporin users also had a reduction in risk compared to non-users (OR=0.45; 95% 
CI: 0.14, 1.42). A small reduction in risk was also observed for the antibiotic NOS group 
(OR=0.87; 95% CI: 0.71, 1.07) as well as for the miscellaneous antibacterial users 
(OR=0.69; 95% CI: 0.30, 1.60) (Table 4.11a) compared to non-users. After adjusting for 
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other classes, the reduction in risk remained for macrolides users (OR=0.73, 95% CI: 
0.42, 1.29) and cephalosporin users (OR=0.50; 95% CI: 0.15, 1.64) compared to non-
users (Table 4.11b). 
 Analysis of indication for antibiotic use among antibiotic users revealed that 
mothers who took antibiotics during pregnancy for respiratory infections were less likely 
to give birth to SGA infants compared to mothers who took antibiotics during pregnancy 
for other indications (OR=0.80; 95% CI: 0.60, 1.08) (Table 4.12a) and less likely to give 
birth to SGA infants compared to mothers who reported no antibiotic use during 
pregnancy (OR=0.76; 95% CI: 0.60, 0.97) (Table 4.12b). Conversely, mothers who took 
antibiotics during pregnancy for genitourinary infections were slightly more likely to give 
birth to SGA infants compared to mothers who took antibiotics during pregnancy for 
other indications (OR=1.18; 95% CI: 0.88, 1.59) (Table 4.12a); however, the risk of 
giving birth to and SGA infant was virtually the same when compared to mothers who 
reported no antibiotic use during pregnancy (OR=0.93; 95% CI: 0.74, 1.16) (Table 
4.12b). 
 Antibiotic class, duration, and indication for use were examined in a model 
together in order to adjust for the effects of the other, with no use at any time in 
pregnancy as the reference category. Given the small number of reports, in these models, 
cephalosporin class antibiotics were group with ‘other antibiotic’. These models were 
stratified by trimester, and for subjects with multiple exposures in a single trimester, only 
the first was considered. In the first trimester, a notable difference after adjustment for 
other characteristics of exposure was that short and long duration (1–6 days; 11+ days) 
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were associated with an increase in risk of SGA compared to women who did not report 
any antibiotic use during pregnancy (OR=1.62; 95% CI: 0.95, 2.77; OR=1.75; 95% CI: 
0.94, 3.26) (Table 4.13a). Using antibiotics for genitourinary infections in the second 
trimester was associated with an increased risk for SGA (OR=1.94; 95% CI: 0.97, 3.87) 
compared to non-users (Table 4.13b), whereas genitourinary infections were associated 
with a reduction of risk for SGA in the first trimester (OR=0.94; 95% CI: 0.54, 1.64) 
(Table 4.13a). Lastly, in the third trimester, duration of use (1–6 days) was associated 
with a reduction in risk of SGA compared to mothers who reported no antibiotic use 
during pregnancy (OR=0.70; 95% CI: 0.36, 1.36). Mothers who reported antibiotic use 
for genitourinary infections had over a two-fold increase in risk of giving birth to an SGA 
infant (OR=2.26; 95% CI: 1.07, 4.76) compared to mothers who did not report antibiotic 
use during pregnancy (Table 4.13c). 
 
 
4.4 DISCUSSION 
In this large sample of 10,647 singleton infants from the BDS, we observed that antibiotic 
use during pregnancy was associated with a reduction in risk of SGA. Stratified analysis 
revealed this association was similar across maternal smoking status during pregnancy 
and infant sex. Further analysis revealed antibiotic use during pregnancy had little 
association with birthweight adjusted for gestational age z-score. Analysis examining 
timing of antibiotic exposure revealed no association between antibiotic use and SGA in 
the first and second trimesters. Antibiotic use during the third trimester was associated 
with a reduction in risk of SGA. A dose-response relationship with duration was not 
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observed. Penicillin class use was nearly equivalent to no antibiotic use during pregnancy 
in terms of SGA risk, while macrolides and cephalosporin class use were each associated 
with a reduction in risk of SGA compared to no use during pregnancy. In analysis 
stratified by trimester, using antibiotics for 1–6 days in the third trimester was associated 
with a reduction in risk of SGA and using antibiotics to treat a genitourinary infection in 
the third trimester was associated with an increase in risk of SGA. 
 Previous studies examining the association between antibiotic use during 
pregnancy and birthweight have found conflicting results. These conflicting results may 
be explained, in part, by different definitions of the outcome, timing of exposure, 
reference group, and sample size. One study of 2,128 pregnant women from the Project 
Viva cohort found that antibiotic use during pregnancy was associated with lower 
BW/GA-z (β= -0.11, 95% CI: -0.20, -0.01)11, calculated using the growth curves 
developed by Oken, et al.14 In a sensitivity analysis, we examined the association 
between antibiotic use during pregnancy and BW/GA-z, calculated using the same 
growth curves14 and found no association. There were many similarities between our 
study and the study by Mueller, et al. (Project Viva cohort). Both were observational 
cohort studies and both restricted analyses to singleton births. Study population 
demographics were also quite similar, specifically with regards to the proportion of each 
sample that was white, average maternal age and pre-pregnancy BMI, proportion of 
college educated parents, gestational age at delivery, and proportion of mothers who took 
antibiotics during pregnancy. One possible explanation for our different conclusions 
could be misclassification of exposure and outcome in our study. In the Project Viva 
  
91 
cohort, antibiotic use during pregnancy was obtained through electronic medical records 
(EMR) and birthweight was obtained through hospital medical records.11 In our study, 
antibiotic use during pregnancy and birthweight were self-reported by the mother. It is 
possible that mothers of SGA infants differentially recalled antibiotic exposure during 
pregnancy, therefore, possibly overstating the observed protective effect of antibiotics on 
SGA in our study. Other differences included our larger study population (N=10,647 vs. 
N=2,128) and geographical diversity. Our study includes women from Boston, New 
York, Philadelphia, Toronto, Iowa, Tennessee and San Diego, whereas the Project Viva 
cohort was exclusively drawn from Massachusetts. It is possible this relationship could 
have geographic variability. 
 Mueller, et al. observed a reduction in BW/GA-z score among antibiotic users 
compared to non-users (β= -0.11, 95% CI: -0.20, -0.01) that was driven by second 
trimester use (β= -0.23, 95% CI: -0.37, -0.08).11 Although authors in the Project Viva 
Study did observe a statistically significant result, it is important to bring this into the 
context of clinical significance. Overall, infants exposed to antibiotics in utero had 
BW/GA-z scores about one-ninth of a standard deviation lower than those of infants not 
exposed to antibiotics in utero. Infants exposed to antibiotics in the second trimester had 
BW/GA-z scores about one-fourth of a standard deviation lower than those of infants not 
exposed to antibiotics in utero. 
 Another study using birthweight as a continuous outcome measure observed that 
infants born to mothers who used antibiotics during pregnancy weighed, on average, 42.1 
grams (SE=37.4) less at birth compared to mothers who did not use antibiotics during 
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pregnancy; however, this effect size is only approximately 0.09 lbs.1 As a sensitivity 
analysis, we examined birthweight (in grams) as a continuous outcome measure and 
adjusted for gestational age (in weeks) in our fully adjusted model (Table 4.7). We, in 
fact, observed a slight increase in birthweight for antibiotic users compared to non-users. 
We opted against using birthweight as a continuous outcome measure and adjusting for 
gestational age because this method assumes a linear relationship between birthweight 
and gestational age, and considering it like a confounder violates causal theory.14 A few 
key differences in our study populations could explain the conflicting results between our 
study and that by Nelson, et al. The distribution of antibiotic class was different; we had 
nearly half of mothers unable to accurately recall the antibiotic they took during 
pregnancy, whereas Nelson, et al. only reported 19%.1 This could reduce the precision of 
our estimates for specific antibiotic classes because some of the subjects truly exposed to 
a given class are appearing in the antibiotic-NOS group.1  
The NEST study, a prospective cohort study, examined 396 full term (gestational 
age ≥ 37 weeks) infants and evaluated the association between maternal antibiotic use 
during pregnancy and infant birthweight. Authors observed that infants exposed to 
antibiotics in utero weighed, on average, 133 g (SE=50.70) less at birth compared to 
infants not exposed to antibiotics in utero; however, this effect size is roughly equivalent 
to  0.3 lbs.2 We observed virtually no association in our sensitivity analysis examining 
birthweight adjusted for gestational age. As a further sensitivity analysis, we restricted 
our population to full term infants, as was done in the NEST study2, and still observed no 
association between antibiotic use during pregnancy and birthweight. In our study, we 
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examined antibiotic use throughout the course of pregnancy, while the NEST study only 
examined exposure up to 30 weeks of gestation.2 We did observe that 1–6 days of use 
(compared to no use at all during pregnancy) in the first trimester of pregnancy was 
associated with an increase in risk of SGA. Conversely, 1–6 days of use in the third 
trimester (which is mostly excluded in the NEST study by restricting the exposure 
window to the first 30 weeks) was associated with a reduction in risk of SGA. It is likely 
our different exposure periods explain some of the differences observed between our 
studies. Both our study and the NEST study relied on self-report of maternal antibiotic 
use during pregnancy, however, our study relied on maternal self-report for birthweight 
as well, whereas the NEST study obtained information on infant birthweight from 
medical records.2 Other differences include our larger sample size (N=10,647 vs. 
N=396), and greater prevalence of exposure (25.1% vs. 20.7%). 
Another study of 10,638 Danish women found that exposure to amoxicillin during 
gestation was associated with a reduction in risk of low birthweight (<2500 grams) 
(OR=0.63; 95% CI=0.26, 1.53) compared to infants not exposed to any prescription 
medication during pregnancy (including antibiotics) in their analysis restricted to full 
term infants (≥ 37 weeks gestational age).9 In our analysis, we observed a reduction in 
risk of SGA for penicillin users compared to antibiotic non-users for the first and second 
trimesters of pregnancy, although the magnitude of our protective effect was smaller. 
Jepsen, et al. compared amoxicillin class users to non-users of any prescription 
medications of any kind throughout pregnancy, rather than just antibiotic non-users, as 
we did. For this reason, authors of the study acknowledged that the effect of amoxicillin 
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observed could be inflated.9  
There were numerous strengths of our study. We had a large, racially and 
ethnically diverse study population, representative of multiple geographic regions across 
the U.S. and Canada. We also had information on maternal antibiotic use throughout the 
entire duration of pregnancy. Information was available on various characteristics of 
antibiotic exposure including trimester of use, duration of use, class of antibiotic, 
indication for use. Many prior studies lacked information on these exposure 
characteristics and cited this as an important limitation. We were also able to examine the 
outcome in various ways. We used SGA as our primary outcome, but also examined 
birthweight (g), birthweight (g) adjusted for gestational age (weeks), birthweight 
stratified by term (preterm: <37 weeks; full-term: ≥ 37 weeks), and BW/GA-z. Finally, 
data were available on numerous potential confounders including maternal smoking 
status during pregnancy and parental education. 
Our study was not without limitations. Both our exposure, maternal antibiotic use 
during pregnancy, and our outcome, SGA, relied on self-report by the mother. Infant 
birthweight has been shown to be recalled reliably by mothers.16 However, recall 
accuracy with respect to details regarding antibiotic use (trimester of use, indication for 
use, duration of use, class of antibiotic used) may be poor. We also cannot rule out 
residual or unmeasured confounding. Additionally, we did not control for use of other 
prescription medications during pregnancy, which could have an association with 
birthweight. We also were unable to fully control for confounding by indication as we did 
not have information on infections for mothers who did not report antibiotic use during 
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pregnancy. 
In summary, we observed a reduction in risk of SGA for mothers who reported 
antibiotic use during pregnancy. Results varied by trimester of use, class of antibiotic use, 
and indication for antibiotic use. Future studies should evaluate this relationship 
prospectively and rely on prescription databases and electronic medical records to 
eliminate the potential for recall bias and measurement error. Additionally, future 
prospective studies should examine if this association is modified by probiotic use during 
pregnancy. Understanding the effect maternal antibiotic use during pregnancy has on 
infant birthweight and SGA, and determining if this is the result of antibiotics altering the 
infant gut microbiota, has important public health implications. If there is a true causal 
association between maternal antibiotic use and birthweight, this should factor into a 
physician’s decision when evaluating the risks and benefits of prescribing antibiotics to 
an expectant mother.  
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Table 4.1 Distribution of covariates by SGA* (Small for Gestational Age) for 
singleton infants in the Birth Defects Study (BDS) control population 
 SGA (n=891) Not SGA (n=9,756) 
Infant exposed to antibiotics during gestation   
   Yes 208 (23.3%) 2,469 (25.3%) 
Infant sex   
   Male 456 (51.2%) 4,792 (49.1%) 
   Female 435 (48.8%) 4,964 (50.9%) 
Gestational age (weeks) 39.1 ± 1.8 39.4 ± 1.7 
Preterm (<37 weeks) 75 (8.6%) 582 (6.0%) 
Birthweight (g) 2,606 ± 337 3,477 ± 487 
BW/GA  z-scorea -1.7 ± 0.3 0.2 ± 0.8 
Mother’s age 27.5 ± 6.4 29.3 ± 5.7 
Mother’s pre-pregnancy BMI 23.9 ± 5.4 24.6 ± 5.3 
Mother’s pre-pregnancy weight statusb   
   Underweight 72 (8.1%) 429 (4.4%) 
   Normal weight 566 (63.5%) 5,942 (60.9%) 
   Overweight 144 (16.2%) 2,059 (21.1%) 
   Obese 109 (12.2%) 1,326 (13.6%) 
Maternal weight gain during pregnancy (lbs) 29.1 ± 16.5 33.1 ± 15.1 
Maternal weight gain during pregnancyc   
    Less than recommended 290 (32.6%) 1,813 (18.6%) 
    Recommended 250 (28.1%) 2,811 (28.8%) 
    More than recommended 351 (39.4%) 5,132 (52.6%) 
Mother smoked during pregnancy 115 (12.9%) 637 (6.5%) 
Mother’s race/ethnicity   
   White 449 (50.4%) 6,964 (71.4%) 
   Black 145 (16.3%) 819 (8.4%) 
   Asian 95 (10.7%) 572 (5.9%) 
   Nat Am/PacIsl/Other/Multi 120 (13.4%) 844 (8.6%) 
   Hispanic 82 (9.2%) 557 (5.7%) 
Highest parental education level   
    Less than high school 78 (8.7%) 438 (4.5%) 
    High school degree 249 (28.0%) 1,648 (16.9%) 
    Some college 183 (20.5%) 1,901 (19.5%) 
    College plus 381 (42.8%) 5,769 (59.1%) 
*SGA defined using the growth curves developed by Oken (SGA<10th percentile for weight)14 
aBirthweight- for-gestational age z-score; calculated using the growth curves developed by 
Oken.14 
bUsing mother’s pre-pregnancy BMI. 
c Using IOM 2009 Guidelines.17 
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Table 4.2 Distribution of covariates by exposure to antibiotics during gestation for 
infants in the Birth Defects Study (BDS) control population 
 Exposed to Antibiotics 
During Gestation (n=2,677) 
Not Exposed to Antibiotics 
During Gestation (n=7,970) 
Gestational sizea   
   SGA 208 (7.8%) 683 (8.6%) 
Infant sex   
   Male 1,274 (47.6%) 3,974 (49.9%) 
   Female 1,403 (52.4%) 3,996 (50.1%) 
Gestational age (weeks) 39.3 ± 1.8 39.4 ± 1.7 
Preterm (<37 weeks) 180 (6.8%) 477 (6.0%) 
Birthweight (g) 3398 ± 542 3407 ± 531 
BW/GA  z-scorea 0.06 ± 0.95 0.04 ± 0.96 
Mother’s age 28.9 ± 5.9 29.2 ± 5.7 
Mother’s pre-pregnancy BMI 25.0 ± 5.6 24.3 ± 5.1 
Mother’s pre-pregnancy weight 
status 
  
   Underweight 132 (4.9%) 369 (4.6%) 
   Normal weight 1,504 (56.2%) 5,004 (62.8%) 
   Overweight 616 (23.0%) 1,587 (19.9%) 
   Obese 425 (15.9%) 1,010 (12.7%) 
Maternal weight gain during 
pregnancy (lbs) 
32.4 ± 16.0 32.9 ± 15.0 
Maternal weight gain during 
pregnancyb 
  
    Less than recommended 551 (20.6%) 1,552 (19.5%) 
    Recommended 744 (27.8%) 2,317 (29.1%) 
    More than recommended 1,382 (51.6%) 4,101 (51.4%) 
Mother smoked during 
pregnancy 
252 (9.4%) 500 (6.3%) 
Mother’s race/ethnicity   
   White 1,913 (71.4%) 5,500 (69.0%) 
   Black 267 (10.0%) 697 (8.8%) 
   Asian 131 (4.9%) 536 (6.7%) 
   Nat Am/PacIsl/Other/Multi 230 (8.6%) 734 (9.2%) 
   Hispanic 136 (5.1%) 503 (6.3%) 
Highest parental education level   
    Less than high school 125 (4.7%) 391 (4.9%) 
    High school degree 525 (19.6%) 1,372 (17.2%) 
    Some college 584 (21.8%) 1,500 (18.8%) 
    College plus 1,443 (53.9%) 4,707 (59.1%) 
a Birthweight-for-gestational age z-score; defined according to the growth curves developed by 
Oken.14 
b According to IOM 2009 Guidelines.17 
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Table 4.3 Characteristics of exposure to antibiotics during gestation for control 
subjects in the Birth Defects Study (BDS) control population (N=10,647 subjects) 
Exposure n (%) 
Infant exposed to antibiotics during gestation  
    Not exposed 7,970 (74.9%) 
    Exposed 2,677 (25.1%) 
       Single exposure 2,044 (76.4%) 
       Multiple exposures 633 (23.6%) 
TIMING a, b 
Trimester 1 Exposure  
    Yes  1,074 (49.2%) 
Trimester 2 Exposure  
    Yes  669 (30.7%) 
Trimester 3 Exposure  
    Yes  685 (31.4%) 
No. of trimesters exposed  
    None 7,970 (78.5%) 
    One 1,951 (19.2%) 
    Two 213 (2.1%) 
    Three 17 (0.2%) 
DURATIONc 
    Median (min, max)d 8 (1, 280) 
    1–6 days 734 (28.0%) 
    7–10 days 1130 (43.1%) 
    11+ days 757 (28.9%) 
CLASSe 
    Antibiotic NOS 1,670 (47.9%) 
    Penicillins 895 (25.6%) 
    Macrolides 535 (15.3%) 
    Cephalosporins 91 (2.6%) 
    Miscellaneous Antibacterial 105 (3.0%) 
    Other 194 (5.6%) 
INDICATIONf 
   Respiratory infections 1,499 (43.0%) 
   Genitourinary infections 1,310 (37.5%) 
   Other 681 (19.5%) 
*Core sample of 10,647. 
a There were 496 subjects in our final sample of 10,647 where antibiotic use with uncertain 
exposure periods was reported. Those reports are not classified under any trimester. 
b Percents will add to over 100% because women reported use in multiple trimesters. 
c Duration was summed across the entire pregnancy. 56 subjects reported antibiotic use during 
pregnancy, but had missing values for duration. 
d There were 8 subjects who reported antibiotic use for duration longer than 365 days. These 
subjects were on continuous antibiotics. Because this analysis was restricting to during 
pregnancy, we capped the max at 280 days (40 weeks x 7 days=280 days). 
  
99 
e N may add to more than the number of subjects because women could use antibiotics multiple 
times during pregnancy and the same class of antibiotic may or may not have been prescribed 
each time 
f N may add to more than the number of subjects who used antibiotics because women could have 
multiple indications for use throughout pregnancy 
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Table 4.4 The association between exposure to antibiotics during gestation and 
SGA* for Infants in the Birth Defects Study (BDS) control population 
 Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Exposure to antibiotics 
during gestation 
0.90 (0.77, 1.06) 0.87 (0.74, 1.03) 0.86 (0.73, 1.01) 
Mother smoked during 
pregnancy 
 2.15 (1.74, 2.66) 1.58 (1.26, 1.97) 
Highest parental 
education level 
   
HS degree vs. less than 
high school 
  0.85 (0.64, 1.11) 
    Some college vs. less 
than high school 
  0.56 (0.42, 0.75) 
    College plus vs. less than 
high school 
  0.40 (0.31, 0.52) 
*SGA defined as <10th percentile for gestational age and gender according to the growth curves 
developed by Oken, et al.14 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal smoking during pregnancy and parental education. 
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Table 4.5 The association between exposure to antibiotics during gestation and 
SGA stratified by smoking during pregnancy in the Birth Defects Study (BDS) 
control population 
 Number in 
exposure 
category 
Number 
of SGA 
infants 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Smokers 752 115   
   Not exposed (ref) 500 80 1.00 1.00 
Exposure to 
antibiotics during 
gestation 
252 35 0.85 (0.55, 1.30) 0.81 (0.53, 1.25) 
 
Non-smokers 9,895 776   
   Not exposed (ref) 7,470 603 1.00 1.00 
   Exposure to 
antibiotics during 
gestation 
2,425 173 0.88 (0.73, 1.04) 0.86 (0.72, 1.03) 
Model 1 is unadjusted. 
Model 2 is adjusted for parental education. 
 
 
Table 4.6 The association between exposure to antibiotics during gestation and 
SGA stratified by sex in the Birth Defects Study (BDS) control population 
(n=5,399) 
 Number in 
exposure 
category 
Number 
of SGA 
infants 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% 
CI) 
Females 5,399 435    
Not exposed 
(ref) 
3,996 
328 1.00 1.00 1.00 
   Exposure to 
antibiotics 
during gestation 
1,403 107 0.92 (0.74, 1.16) 
0.89  
(0.71, 1.12) 
0.87  
(0.69, 1.09) 
 
Males 5,248 456    
   Not exposed 
(ref) 
3,974 355 1.00 1.00 1.00 
   Exposure to 
antibiotics 
during gestation 
1,274 101 0.88 (0.70, 1.11) 
0.86  
(0.68, 1.08) 
0.85  
(0.67, 1.07) 
 Model 1 is unadjusted. 
 Model 2 is adjusted for maternal smoking during pregnancy. 
 Model 3 is adjusted for maternal smoking during pregnancy and parental education. 
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Table 4.7 The association between exposure to antibiotics during gestation and 
birthweight (g) in the Birth Defects Study (BDS) control population, N=10,647 
 Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Model 3 
β (95% CI) 
Model 4 
β (95% CI) 
Model 5 
β (95% CI) 
All infantsa   
  Unexposed Ref. Ref. Ref. Ref. Ref. 
  Exposed to 
antibiotics  
-9.18  
(-32.55, 14.19) 
2.10  
(-17.54, 21.74) 
5.38  
(-14.02, 24.79) 
10.99  
(-8.34, 30.32) 
12.27  
(-6.99, 31.53) 
 
Pre-termb 
(<37 weeks) 
Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Model 3 
β (95% CI) 
Model 4 
β (95% CI) 
Model 5 
β (95% CI) 
  Unexposed Ref. Ref. Ref. Ref. Ref. 
  Exposed to 
antibiotics  
-57.89  
(-179.94, 64.16) 
-10.81  
(-94.75, 73.12) 
-5.27  
(-88.94, 78.39) 
-6.34  
(-89.61, 76.93) 
-6.46  
(-89.84, 76.92) 
 
Full termc 
 (≥ 37 weeks) 
Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Model 3 
β (95% CI) 
Model 4 
β (95% CI) 
Model 5 
β (95% CI) 
  Unexposed Ref. Ref. Ref. Ref. Ref. 
Exposed to      
antibiotics 
2.34  
(-18.74, 23.43) 
3.82 
 (-16.27, 23.92) 
6.90  
(-12.94, 26.74) 
12.81  
(-6.96, 32.57) 
14.44  
(-5.23, 34.12) 
a N=10,647 
b n=657 
c n=9,918 
Model 1 is unadjusted. 
Model 2 is adjusted for gestational age (weeks) 
Model 3 is adjusted for gestational age, and sex. 
Model 4 is adjusted for gestational age, sex, and maternal smoking during pregnancy. 
Model 5 is adjusted for gestational age, sex, maternal smoking during pregnancy, and parental 
education. 
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Table 4.8a The association between exposure to antibiotics during gestation and 
birthweight-for-gestational age z-score* in the Birth Defects Study (BDS) control 
population (N=10,647) 
 Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Model 3 
β (95% CI) 
Unexposed Ref. Ref. Ref. 
Exposure to antibiotics 
during gestation 
0.01 (-0.03, 0.05) 0.02 (-0.02, 0.07) 0.03 (-0.01, 0.07) 
*birthweight-for-gestational age z-score calculated using growth curves developed by Oken, et 
al.14 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal smoking during pregnancy and parental education. 
 
 
Table 4.8b The association between exposure to antibiotics during gestation and 
birthweight-for-gestational age z-score* stratified by smoking status during 
pregnancy in the Birth Defects Study (BDS) control population 
 Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Smoker, n=752   
  Unexposed Ref. Ref. 
  Exposure to antibiotics during 
gestation 
-0.03 (-0.17, 0.11) -0.02 (-0.17, 0.12) 
 Model 1 
β (95% CI) 
Model 2 
β (95% CI) 
Non-smoker, n=9,895   
  Unexposed Ref. Ref. 
Exposure to antibiotics during 
gestation 
0.03 (-0.02, 0.07) 0.03 (-0.01, 0.07) 
*birthweight-for-gestational age z-score calculated using growth curves developed by Oken, et 
al.14 
Model 1 is unadjusted. 
Model 2 is adjusted for highest parental education. 
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Table 4.9a Timing of exposure to antibiotics during gestation and the association 
with SGA in the BDS control population (N=10,151)* 
Timinga n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Trimester 1     
  Not Exposed 9,077 1.00 1.00 1.00 
  Exposed 1,074 0.95 (0.76, 1.20) 0.93 (0.74, 1.17) 0.93 (0.74, 1.17) 
Trimester 2     
  Not Exposed 9,482 1.00 1.00 1.00 
  Exposed 669 1.06 (0.81, 1.40) 1.04 (0.79, 1.37) 1.01 (0.76, 1.33) 
Trimester 3     
  Not Exposed 9,466 1.00 1.00 1.00 
  Exposed 685 0.84 (0.63, 1.14) 0.83 (0.61, 1.11) 0.82 (0.61, 1.11) 
*Subjects with uncertain exposure periods were removed from this analysis. 
aThe OR for exposure in each trimester is adjusted for exposure in the other two trimesters. 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal smoking during pregnancy and parental education. 
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Table 4.9b Timing of exposure to antibiotics during gestation and the association 
with SGA in the BDS control population (n=9,921) (restricting to infants exposed to 
antibiotics in only one trimester at any time during gestation) 
Timinga n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Trimester 1     
  Not Exposed 9,018 1.00 1.00 1.00 
  Exposed 903 0.94 (0.73, 1.21) 0.92 (0.71, 1.18) 0.92 (0.71, 1.19) 
Trimester 2     
  Not Exposed 9,405 1.00 1.00 1.00 
  Exposed 516 1.04 (0.76, 1.43) 1.01 (0.74, 1.39) 0.98 (0.71, 1.34) 
Trimester 3     
  Not Exposed 9,389 1.00 1.00 1.00 
  Exposed 532 0.75 (0.53, 1.07) 0.74 (0.52, 1.05) 0.73 (0.51, 1.04) 
*Subjects with uncertain exposure periods were removed from this analysis. 
aThe OR for exposure in each trimester is adjusted for exposure in the other two trimesters. 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal smoking during pregnancy, and parental education. 
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Table 4.10 Duration of exposure to antibiotics during gestation and the association 
with SGA in the BDS control population 
 n Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95%CI) 
Duration     
   0 days  7,970 1.00 1.00 1.00 
   1–6 days 734 0.71 (0.52, 0.97) 0.70 (0.51, 0.95) 0.70 (0.52, 0.96) 
   7–10 days 1,130 0.95 (0.75, 1.19) 0.92 (0.73, 1.16) 0.90 (0.71, 1.13) 
   11+ days 757 1.00 (0.77, 1.31) 0.95 (0.73, 1.25) 0.93 (0.71, 1.21) 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal during pregnancy and parental education. 
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Table 4.11a Class of antibiotic taken during gestation and the association with SGA 
among infants exposed to antibiotics during gestation in the BDS control 
population (N=10,647) 
 
n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Type (class)a     
Penicillins  
No antibiotic use (ref.) 7,970 1.00 1.00 1.00 
Penicillin 789 0.97 (0.75, 1.27) 0.94 (0.72, 1.23) 0.94 (0.72, 1.23) 
Non-penicillin 1,888 0.87 (0.72, 1.05) 0.84 (0.70, 1.02) 0.82 (0.68, 0.99) 
Macrolides  
No antibiotic use (ref.) 7,970 1.00 1.00 1.00 
Macrolides 420 0.59 (0.38, 0.91) 0.59 (0.38, 0.91) 0.65 (0.42, 1.01) 
Non-Macrolides 2,257 0.96 (0.81, 1.14) 0.92 (0.78, 1.10) 0.89 (0.75, 1.06) 
Cephalosporins  
No antibiotic use (ref.) 7,970 1.00 1.00 1.00 
Cephalosporins 84 0.40 (0.12, 1.26) 0.41 (0.13, 1.29) 0.45 (0.14, 1.42) 
Non-Cephalosporin 2,593 0.92 (0.78, 1.08) 0.89 (0.75, 1.04) 0.87 (0.74, 1.02) 
Antibiotic-NOS  
No antibiotic use (ref.) 7,970 1.00 1.00 1.00 
Antibiotic-NOS 1,420 0.97 (0.79, 1.19) 0.93 (0.75, 1.14) 0.87 (0.71, 1.07) 
Antibiotic recalled 1,257 0.82 (0.66, 1.03) 0.81 (0.64, 1.02) 0.84 (0.66, 1.05) 
Miscellaneous 
antibacterials 
 
No antibiotic use (ref.) 7,970 1.00 1.00 1.00 
Misc. antibacterial 97 0.70 (0.31, 1.61) 0.70 (0.31, 1.61) 0.69 (0.30, 1.60) 
Non-misc. antibacterial 2,580 0.91 (0.77, 1.07) 0.88 (0.74, 1.03) 0.86 (0.73, 1.02) 
aAnalyzed as five separate models. 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal smoking during pregnancy, and parental education. 
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Table 4.11b Type of antibiotic taken during gestation and the association with SGA 
among infants exposed to antibiotics during gestation in the BDS control 
population 
 
n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Type (class)  
No antibiotic use 7,970 1.00 1.00 1.00 
Penicillins 789 1.00 (0.76, 1.32) 0.97 (0.74, 1.28) 0.97 (0.74, 1.28) 
Non-penicillins 1,888 0.92 (0.58, 1.46) 0.90 (0.57, 1.42) 0.89 (0.74, 1.41) 
Macrolides 420 0.64 (0.36, 1.12) 0.65 (0.37, 1.14) 0.73 (0.42, 1.29) 
Cephalosporins 84 0.43 (0.13, 1.41) 0.46 (0.14, 1.49) 0.50 (0.15, 1.64) 
Antibiotic NOS 1,420 1.07 (0.67, 1.68) 1.05 (0.66, 1.66) 0.99 (0.63, 1.57) 
Misc. antibacterials 97 0.79 (0.33, 1.90) 0.81 (0.34, 1.95) 0.80 (0.33, 1.94) 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is adjusted for maternal smoking during pregnancy, and parental education 
 
*parameters for macrolides non-users, cephalosporin non-users, antibiotic-NOS non-users, 
miscellaneous antibacterial non-users get dropped out of model because they are a linear 
combination of other parameters (i.e., macrolides non-users are penicillin users+ penicillin non-
users – macrolide users). 
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Table 4.12a Reason for antibiotic taken during gestation and the association with 
SGA among infants exposed to antibiotics during gestation in the BDS control 
population 
 
n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Type (class)  
Other (ref.) 1,434 1.00 1.00 1.00 
Respiratory 
Infections 
1,243 0.72 (0.54, 0.96) 0.73 (0.55, 0.98) 0.80 (0.60, 1.08) 
     
 n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Type (class)     
Other (ref.) 1,568 1.00 1.00 1.00 
Genitourinary 
Infections 
1,109 1.40 (1.05, 1.86) 1.36 (1.02, 1.81) 1.18 (0.88, 1.59) 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is maternal smoking during pregnancy and parental education. 
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Table 4.12b Reason for antibiotic taken during gestation and the association with 
SGA among infants in the BDS control population 
 
n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Type (class)     
Respiratory 
Infections 
    
Unexposed to 
antibiotics 
7,970 1.00 1.00 1.00 
Respiratory Infections 1,243 0.74 (0.59, 0.94) 0.73 (0.57, 0.93) 0.76 (0.60, 0.97) 
Other infection 1,434 1.04 (0.85, 1.26) 1.00 (0.82, 1.22) 0.93 (0.76, 1.14) 
 
 
n 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Model 3 
OR (95% CI) 
Type (class)     
Genitourinary 
Infections 
    
Unexposed to 
antibiotics 
7,970 1.00 1.00 1.00 
Genitourinary 
infections 
1,109 1.08 (0.87, 1.34) 1.03 (0.83, 1.28) 0.93 (0.74, 1.16) 
Other Infections 1,568 0.77 (0.63, 0.96) 0.76 (0.61, 0.94) 0.80 (0.64, 0.99) 
Model 1 is unadjusted. 
Model 2 is adjusted for maternal smoking during pregnancy. 
Model 3 is maternal smoking during pregnancy and parental education. 
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Table 4.13a First trimester antibiotic use: Exploring antibiotic class, indication for 
use, and duration of use in the BDS control population (For subjects with multiple 
uses in a single trimester, only the first use is considered) (n=9,035) 
 
n 
No. 
SGA 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Class  
Non-users* 7,970 683 1.00 1.00 
Penicillins 277 27 0.92 (0.56, 1.50) 0.91 (0.56, 1.50) 
Macrolides 127 4 0.21 (0.07, 0.64) 0.23 (0.08, 0.69) 
Antibiotic NOS 523 45 0.75 (0.44, 1.28) 0.74 (0.43, 1.26) 
Other 138 10 0.51 (0.21, 1.21) 0.53 (0.22, 1.28) 
Duration     
0 days (non-users)* 7,970 683 1.00 1.00 
1–6 days 298 27 1.65 (0.97, 2.81) 1.62 (0.95, 2.77) 
7–10 daysa 573 40 ----- ----- 
11+ days 194 19 1.66 (0.89, 3.08) 1.75 (0.94, 3.26) 
Indication for use     
Antibiotic non-users* 7,970 683 1.00 1.00 
Genitourinary infection 453 38 1.06 (0.61, 1.82) 0.94 (0.54, 1.64) 
Respiratory Infectionb 408 29 ----- ----- 
Other 204 19 1.24 (0.64, 2.40) 1.31 (0.68, 2.54) 
*Antibiotic non-users are subjects who did not report use in any trimester. 
a, bThese covariates were dropped from the model because they were linear combinations of 
other covariates. 
Model 1 is unadjusted. 
Model 2 is adjusted for smoking and parental education. 
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Table 4.13b Second trimester antibiotic use: Exploring antibiotic class, indication 
for use, and duration of use in the BDS control population (For subjects with 
multiple uses in a single trimester, only the first use is considered) (n=8,639) 
 
n No. SGA 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Class  
Non-users* 7,970 683 1.00 1.00 
Penicillins 189 15 0.61 (0.31, 1.21) 0.63 (0.32, 1.25) 
Macrolides 96 8 0.56 (0.23, 1.38) 0.65 (0.27, 1.61) 
Antibiotic NOS 314 32 0.56 (0.28, 1.11) 0.57 (0.29, 1.15) 
Other 70 4 0.25 (0.07, 0.88) 0.28 (0.08, 1.00) 
Duration     
0 days (non-users)* 7,970 683 1.00 1.00 
1–6 days 222 24 1.73 (0.92, 3.24) 1.72 (0.91, 3.22) 
7–10 daysa 349 25 ----- ----- 
11+ days 98 10 1.65 (0.74, 3.66) 1.49 (0.66, 3.33) 
Indication for use     
Antibiotic non-users* 7,970 683 1.00 1.00 
Genitourinary 
infection 
242 31 2.41 (1.22, 4.75) 1.94 (0.97, 3.87) 
Respiratory Infectionb 291 19 ----- ----- 
Other 136 9 1.00 (0.43, 2.33) 0.93 (0.40, 2.20) 
*Antibiotic non-users are subjects who did not report use in any trimester. 
a, bThese covariates were dropped from the model because they were linear combinations 
of other covariates. 
Model 1 is unadjusted. 
Model 2 is adjusted for smoking and parental education. 
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Table 4.13c Third trimester antibiotic use: Exploring antibiotic class, indication for 
use, and duration of use in the BDS control population (For subjects with multiple 
uses in a single trimester, only the first use is considered) (n=8,655) 
 
n No. SGA 
Model 1 
OR (95% CI) 
Model 2 
OR (95% CI) 
Class  
Non-users* 7,970 683 1.00 1.00 
Penicillins 196 20 1.03 (0.57, 1.89) 1.06 (0.58, 1.95) 
Macrolides 97 7 1.03 (0.42, 2.54) 1.12 (0.45, 2.79) 
Antibiotic NOS 330 20 0.48 (0.23, 1.01) 0.47 (0.22, 0.99) 
Other 62 3 0.42 (0.11, 1.61) 0.50 (0.13, 1.91) 
Duration     
0 days (non-users)* 7,970 683 1.00 1.00 
1–6 days 295 19 0.64 (0.33, 1.24) 0.70 (0.36, 1.36) 
7–10 daysa 320 29 ----- ----- 
11+ days 70 2 0.26 (0.06, 1.15) 0.25 (0.06, 1.12) 
Indication for use     
Antibiotic non-users* 7,970 683 1.00 1.00 
Genitourinary 
infection 
234 22 2.71 (1.28, 5.71) 2.26 (1.07, 4.76) 
Respiratory Infectionb 300 18 ----- ----- 
Other 151 10 1.56 (0.66, 3.69) 1.37 (0.58, 3.24) 
*Antibiotic non-users are subjects who did not report use in any trimester. 
a,bThese covariates were dropped from the model because they were linear combinations 
of other covariates. 
Model 1 is unadjusted. 
Model 2 is adjusted for smoking and parental education. 
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4.5 APPENDIX 
Appendix 1. 
 
Accutane 
Acetaminophen 
Actron 
Acyclovir 
Advair 
Advil 
Aerobid 
Afrin 
Albuterol 
Aleve 
Alka-seltzer 
Allegra 
Amitriptyline 
Aspirin 
Azmacort 
Bayer 
Beclomethasone 
Bufferin 
Celexa 
Chlor-trimeton 
Claritin 
Cromolyn 
Cymbalta 
Datril 
Dristan 
Ecotrin 
Effexor 
Elamar 
Elavil 
Excedrin 
Fever relievers 
Foradil 
Ibuprofen 
Intal 
Lexapro 
Luvox 
Motrin 
Naprosyn 
Nasalcrom 
Nuprin 
Orudis 
Other acetaminophen products 
Other aspirin products 
Other ibuprofen products 
Other Naproxen products 
Other pain products 
Panadol 
Paxil 
Pepto Bismol 
Peramivir 
Pristiq 
Prozac 
Relenza 
Retin-A 
Serevent 
Singulair 
Slo-bid 
Sudafed/pseudophedrine 
Symbicort 
Tamiflu 
Theo-dur 
Tylenol 
Tylenol products 
Valcyclovir 
Valtrex 
Wellbutrin 
Zoloft 
Zovirax 
Zyban 
Zyrtec 
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Appendix 2. 
 
V1: 
     Ampicillin 
     Amoxicillin 
     Augmentin 
     Erythromycin 
     Bactrim 
     Septra 
     Sulfamethoxazole 
     Flagyl 
     Protostat 
     Metronidazole 
     Zithromax 
 
V11: 
     Ampicillin 
     Amoxicillin 
     Augmentin 
     Erythromycin 
     Bactrim 
     Flagyl 
     Metronidazole 
     Zithromax 
 
V20.6: 
 Amoxicillin, Ampicillin, Penicillin (Trimox), Dicloxicillin 
 Zithromax, Z-Pak  
 Augmentin (amoxicillin-clavulanate)   
 Bactrim (TMP/trimethoprim/sulfamethoxazole) 
 Erythromycin (EC, EES) 
 Macrobid (Nitrofurantoin) 
 Keflex (Cephalexin) 
 Ceclor (Cefaclor) 
 Clindamycin (Clindamycin) 
 Biaxin (Clarithromycin) 
 Cipro (Ciprofloxacin)  
 Flagyl (Metronidazole) 
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V21: 
 Amoxicillin, Ampicillin, Penicillin (Trimox), Dicloxicillin 
 Zithromax, Z-Pak  
 Augmentin (amoxicillin-clavulanate)   
 Bactrim (TMP/trimethoprim/sulfamethoxazole) 
 Erythromycin (EC, EES) 
 Macrobid (Nitrofurantoin) 
 Keflex (Cephalexin) 
 Ceclor (Cefaclor) 
 Clindamycin (Clindamycin) 
 Biaxin (Clarithromycin) 
 Cipro (Ciprofloxacin)  
 Flagyl (Metronidazole) 
 
Topical Antib.:   
Benzamycin, Akne-mycin, T-stat  
Cleocin T 
Benzaclin 
Metrogel (Metronidazole)  
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Appendix 3. List of Antibiotic Classes 
 
 
 
 
 
 
 
 
  
Amebicides 
Aminoglycosides 
Anti-bacterials 
Anti-mycobacterials 
Anti-protozoals 
Anti-tuberculosis 
Cephalosporins 
Macrolides 
Antibiotic-NOS (not otherwise specificed) 
Miscellaneous anti-mycobacterials 
Penicillins 
Quinolones 
Sulfonamides 
Tetracyclines 
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Appendix 4. List of Indications for Antibiotic Use 
 
 
 
 
 
 
 
  
Respiratory: 
Cold, flu, cough, bronchitis, pneumonia, sinus infection, congestion 
The flu 
Cold, cough, bronchitis, pneumonia, sinus infection, congestion 
Allergies 
*allergy with cold 
Ear infection 
*ear infection with cold 
Strep throat 
*strep throat with cold 
Asthma 
*asthma with allergy 
*asthma with cold 
*asthma, allergy, cold 
Genitourinary: 
urinary tract infection 
vaginal infection 
genital herpes 
other STD 
genital herpes (recurrence) 
gynecological procedure 
other menstrual problems 
Other: 
Chicken Pox 
Antibiotics/med for infection 
Toxemia/Preeclampsia/HELLP syndrome 
Oral herpes/cold sores 
Nausea and/or vomiting 
Vaginal bleeding during pregnancy 
Stomach flu/virus 
Fever at any time 
Nausea 
Diarrhea 
Medicine for hospital prior to delivery 
Infertility  
Other medical procedures 
Infertility procedure  
Other indication 
toothache  
Joint or muscle pain/sprains/injury 
Other pains                                                                          To prevent miscarriage 
Itching                                                                                 To stop labor or contractions 
Ulcers                                                                                  Acne 
Other stomach problems                                                     Other skin problems 
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5. CONCLUSION 
 The studies in this dissertation explored three different exposures at three distinct 
periods in childhood and the corresponding associations with weight or biomarkers of 
metabolic status. We examined the association between PA and MetS among overweight 
adolescents ages 12–19, the association between ETS and overweight among young 
children ages 3–6, and then association between exposure to antibiotics in utero and small 
for gestational age. 
 In our first study examining the association between PA and MetS among 12–19-
year-old adolescents in the NHANES study population, we observed that modest amounts 
of MVPA were associated with a reduced risk of MetS. The inverse relationship was 
present among subgroups of boys, girls, and those with and without food insecurity. We 
observed that vigorous physical activity was driving this association. Our study 
population was racially and ethnically diverse, and one of the first studies we are aware 
of to consider the effects of sexual maturation in females on the association between PA 
and MetS. We observed that whether the female had experienced early menarche (<12) 
did not appreciably alter the association between PA and MetS. The cross-sectional 
design of our study was a limitation; however, we believe reverse causality is an unlikely 
explanation for our observed results given the similar findings reported by prospective 
observational cohort studies1–3 and the similar inverse association observed in each 
population subgroup when we stratified on obesity severity. 
 In our second study examining the association between ETS and overweight 
among 3–6 year olds in NHANES, we found a positive association between ETS and risk 
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of overweight/obesity, with a dose-response relationship observed. Given the cross-
sectional nature of our design, we cannot establish temporality of this association; 
however, we believe reverse causality is unlikely given that our results were consistent 
with findings observed by other prospective observational cohort studies.4–6 A major 
strength of our study was our ability to use serum cotinine to define the exposure rather 
than relying on self-report of tobacco use by adults in the household. Since this exposure 
is often underreported, exposure measurement error is a real concern of prior studies. 
Serum cotinine also captures average daily exposure and doesn’t limit the exposure 
assessment to the child’s primary residence. In our study, we examined the association 
between self-reported smokers in the household and serum cotinine levels. While the two 
were highly correlated, we observed that a significant percentage of subjects with the 
highest serum cotinine levels were from households that reported no smokers, meaning 
that children were being exposed to ETS outside of the home. The dose-response 
relationship observed between serum cotinine and child overweight/obesity was not 
detected using the self-reported exposure assessment, validating concerns about 
misclassification of tobacco use and underreporting of use in prior studies. Although we 
could not rule out the influence of residual and unmeasured confounding, the biologic 
rationale exists to suggest that the inflammatory effects of tobacco smoke influence the 
child’s weight and biomarkers of metabolic health status.4, 6–7 
 Lastly, in our third study, we observed that infants exposed to antibiotic use in 
utero had a reduced risk of SGA. We did not observe an association with birthweight or 
BW/GA-z score as has been reported in other studies.8–11 Our study is the largest we are 
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aware of that has explored this relationship. Previous studies on maternal antibiotic use 
during pregnancy and birthweight have used different outcomes (SGA, low birthweight, 
birthweight adjusted for gestational age, and BW/GA-z score) making cross comparisons 
difficult.8–11 Additionally, these studies have been limited in the characteristics of 
antibiotic exposure that they can assess. With our data, we were able to evaluate trimester 
of exposure, duration, class, and indication for use. We observed that the association 
between class, duration, and indication for use with SGA varied substantially across 
trimesters.  
 In summary, we explored exposures at different stages of childhood and 
development and their relationship with weight and metabolic biomarkers. We were able 
to study PA and MetS in a racially and ethnically diverse population and study the effects 
of sexual maturation in females on this association, addressing limitations of previous 
studies. We also studied the association between ETS and overweight using a biologic 
marker of ETS exposure rather than relying on self-report, reducing measurement error 
that has plagued prior studies. Lastly, our study of maternal antibiotic use during 
pregnancy and SGA was one of the largest studies we are aware of that explored this 
relationship. The results of these studies serve as a complement to the growing body of 
literature on pediatric obesity. 
  
  
124 
5.1 REFERENCES 
1. Peplies J, Bornhorst C, Gunther K, et al. Longitudinal associations of lifestyle 
factors and weight status with insulin resistance (HOMA-IR) in preadolescent 
children: the large prospective cohort study IDEFICS. International Journal of 
Behavioral Nutrition and Physical Activity. 2016 Sep; 13(1): 97. 
2. Hidalgo-Santamaria M, Fernandez-Montero A, Martinez-Gonzalez M, et al. 
Exercise Intensity and Incidence of Metabolic Syndrome: The SUN Project. 
American Journal of Preventive Medicine. 2017 Jan 9. [epub ahead of print]. 
3. Laursen A, Kristiansen O, Marott J, et al. Intensity versus duration of physical 
activity: implications for the metabolic syndrome. A prospective cohort study. 
BMJ Open. 2012 Oct 8; 2(5): e001711. 
4. Pagani L, Nguyen AK, Fitzpatrick C. Prospective Associations Between Early 
Long-Term Household Tobacco Smoke Exposure and Subsequent Indicators of 
Metabolic Risk at Age 10. Nicotine and Tobacco Research. 2016 May; 18 (5): 
1250–1257 
5. Steur M, Smit H, Schipper C, Scholtens S, et al. Predicting the risk of newborn 
children to become overweight later in childhood: The PIAMA birth cohort study. 
International Journal of Pediatric Obesity. 2011 Jun; 6(2–2): e170–e178. 
6. McConnell R, Shen E, Gilliland F, Jerrett M, et al. A Longitudinal Cohort Study 
of Body Mass Index and Childhood Exposure to Secondhand Tobacco Smoke and 
Air Pollution: The Southern California Children’s Health Study. Environmental 
Health Perspectives. 2015 Apr; 123(4): 360–366.  
7. Bolton J, Smith S, Huff N. Prenatal air pollution exposure induces 
neuroinflammation and predisposes offspring to weight gain in adulthood in a 
sex-specific manner. FASEB Journal: Official Publication of the Federation of 
American Societies for Experimental Biology. 2012 Nov; 26 (11): 4743–4754. 
8. Nelson J, Werler M. Socioeconomic Status as a Modifier of the Relationship 
between Antibiotic Use During Pregnancy and Birthweight. Birth. 2008 Sep; 
35(3): 196–203. 
9. Czeizel A, Rockenbauer M, Olsen J. Use of antibiotics during pregnancy. 
European Journal of Obstetrics and Gynecology and Reproductive Biology. 1998 
Oct; 81(1): 1–8. 
10. Vidal AC, Murphy SK, Murtha AP, et al. Associations between antibiotic 
exposure during pregnancy, birth weight and aberrant methylation at imprinted 
  
125 
genes among offspring. International Journal of Obesity. 2013 Jul; 37(7): 907–
913. 
11. Mueller NT, Rifas-Shiman SL, Blaser MJ, et al. Association of prenatal 
antibiotics with foetal size and cord blood leptin and adiponectin. Pediatric 
Obesity. 2017 Apr; 12(2): 129–136. 
  
126 
BIBLIOGRAPHY 
 
Adegboye ARA and Heitmann BL. Accurary and correlates of maternal recall of 
birthweight and gestational age. British Journal of Obstetrics and Gynaecology. 2008 
Jun; 115(7): 886–893. 
 
Agricultural Research Service, Beltsville Human Nutrition Research Center, Food 
Surveys Research Group, Beltsville, MD. USDA Food and Nutrient Database for Dietary 
Studies. http://www.ars.usda.gov/ba/bhnrc/fsrg 
Ajslev TA, Andersen CS, Gamborg M, Sorensen TIA, et al. Childhood overweight after 
establishment of the gut microbiota: the role of delivery mode, pre-pregnancy weight and 
early administration of antibiotics. International Journal of Obesity. 2011 Apr; 35(4): 
522–529. 
 
Alberti KGMM, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome. 
Circulation. 2009 Oct 20; 120(16):1640–1645. 
 
Alberti KGMM, Zimmet PZ. Definition, Diagnosis and Classification of Diabetes 
Mellitus and its Complications Part 1: Diagnosis and Classification of Diabetes Mellitus 
Provisional Report of a WHO Consultation. Diabetic Medicine. 1998 Jul; 15(7): 539–
553. 
 
Amemiya S, Dobashi A, Urakami T, et al. Metabolic Syndrome in Youths. Pediatric 
Diabetes. 2007 Dec; 8(Suppl. 9): 48–54. 
 
American Hospital Formulary Service (AHFS). http://www.ahfsdruginformation.com/. 
Accessed 26 Feb 2017. 
 
American Society for Clinical Nutrition. Clinical Guidelines on the Identification, 
Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary. 
The American Journal of Clinical Nutrition. 1998 Oct; 68(4): 899–917. 
 
Armougom F, Henry M, Vialettes B, Raccah D, et al. Monitoring bacterial community of 
human gut microbiota reveals an increase in lactobacillus in obese patients and 
methanogens in anorexic patients. PLoS One. 2009 Sep 23; 4(9): e7125. 
 
Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: 
European Group for the Study of Insulin Resistance (EGIR). Diabetic Medicine. 1999 
May; 16(5): 442–443. 
 
  
127 
Bamia C, Tricholpoulou A, Lenas D, et al. Tobacco Smoke in relation to body fat mass 
and distribution in a general population sample. International Journal of Obesity and 
Related Metabolic Disorders. 2004 Aug; 28(8):1091–1096. 
 
Bammann K, Peplies J, De Henauw S, et al. Early Life Course Risk Factors for 
Childhood Obesity: The IDEFICS Case-Control Study. PLoS One. 2014 Feb 13; 9(2): 
e86914. 
 
Behl M, Rao D, Aagaard K, et al. Evaluation of the Association Between Maternal 
Smoking, Childhood Obesity, and Metabolic Disorders: A National Toxicology Program 
Workshop Review. Environmental Health Perspectives. 2013 Feb; 121(2): 170–180. 
 
Benowitz N. Cotinine as a Biomarker of Environmental Tobacco Smoke Exposure. 
Epidemiological Reviews. 1996; 18(2): 188–204. 
 
Bolton J, Smith S, Huff N. Prenatal air pollution exposure induces neuroinflammation 
and predisposes offspring to weight gain in adulthood in a sex-specific manner. FASEB 
Journal. 2012 Nov; 26(11): 4743–4754. 
 
Cárdenas-Cárdenas LM, Burguete-Garcia AI, Estrada-Velasco BI, López-Islas C, et al. 
Leisure-time physical activity and cardiometabolic risk among children and adolescents. 
Jornal de Pediatria (Rio de Janeiro). 2015 Mar–Apr; 91(2): 136–142. 
 
Centers for Disease Control and Prevention (CDC). National Center for Health Statistics 
(NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. 
Department of Health and Human Services, Centers for Disease Control and Prevention, 
2007–2012. https://www.cdc.gov/nchs/nhanes/index.htm. 
 
Centers for Disease Control and Prevention (CDC). National Center for Health Statistics 
(NCHS). National Health and Nutrition Examination Survey Questionnaire. Hyattsville, 
MD: U.S. Department of Health and Human Services, Centers for Disease Control and 
Prevention, 2016. https://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm 
 
Centers for Disease Control and Prevention (CDC). National Health and Nutrition 
Examination Survey. Anthropometry Procedures Manual. 2011. Available at: 
https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/Anthropometry_Procedures_Manu
al.pdf. Accessed January 13, 2017.  
 
Centers for Disease Control and Prevention (CDC). National Health and Nutrition 
Examination Survey. Laboratory Procedures Manual. 2011. Available at: 
https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/2011-
12_Laboratory_Procedures_Manual.pdf. Accessed January 13, 2017. 
 
  
128 
Centers for Disease Control and Prevention (CDC). National Health and Nutrition 
Examination Survey. OGTT: Trutol Administration. 2011. Available at: 
https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/Oral_Glucose_Tolerance_Test_(O
GTT)_Manual.pdf. Accessed January 13, 2017. 
 
Centers for Disease Control and Prevention (CDC). National Health and Nutrition 
Examination Survey. MEC In-Person Dietary Interviewers Procedures Manual. 2012. 
Available at: 
https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/mec_in_person_dietary_procedure
s_manual_jan_2012.pdf. Accessed January 13, 2017. 
 
Centers for Disease Control and Prevention (CDC). National Health and Nutrition 
Examination Survey. Phone Follow-Up Dietary Interviewer Procedures Manual. 2012. 
Available at: https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/Phone_Follow-
up_Dietary_Procedures.pdf. Accessed January 13, 2017. 
 
Centers for Disease Control and Prevention (CDC). National Health and Nutrition 
Examination Survey. Physician Examination Procedures Manual. 2011. Available at: 
https://www.cdc.gov/nchs/data/nhanes/nhanes_11_12/Physician_Exam_Manual.pdf. 
Accessed January 13, 2017.  
 
Centers for Disease Control and Prevention. Healthy Weight. 
<http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.h
tml> Accessed November 2014. 
 
Czeizel A, Rockenbauer M, Olsen J. Use of antibiotics during pregnancy. European 
Journal of Obstetrics and Gynecology and Reproductive Biology. 1998 Oct; 81(1): 1–8. 
 
Dubois L, Girard M. Early determinants of overweight at 4.5 years in a population based 
longitudinal study. International Journal of Obesity. 2006 Apr; 30(4): 610–617. 
 
Freedman D, Khan L, Serdula M, et al. The Relation of Childhood BMI to Adult 
Adiposity: The Bogalusa Heart Study. Pediatrics. 2005 Jan; 115:22–27. 
 
Fryar CD, Gu Q, Ogden CL. Anthropometric reference data for children and adults: 
United States, 2007-2010. National Center for Health Statistics. Vital Health Statistics. 
2012; 11(252). 
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and Management of the Metabolic 
Syndrome an American Heart Association/National Heart, Lung, and Blood Institute 
Scientific Statement. Circulation. 2005 Oct 25; 112(17): 2735–2752. 
 
  
129 
Guenther P, Kirkpatrick S, Reedy J, et al. The Healthy Eating Index-2010 Is a Valid and 
Reliable Measure of Diet Quality According to the 2010 Dietary Guidelines for 
Americans. The Journal of Nutrition. 2014 Mar; 144(3): 399–407. 
 
Harris K, King R, Gordon-Larsen P. Healthy Habits Among Adolescents: Sleep, 
Exercise, Diet, and Body Image. For Indicators of Positive Development Conference. 
March 12–13, 2003. Available at: http://childtrends.org/wp-
content/uploads/2013/05/Child_Trends-2003_03_12_PD_PDConfHKGL.pdf. Accessed 
January 29, 2017. 
 
Haughton C, Wang ML, and Lemon SC. Racial/Ethnic Disparities in Meeting 5-2-1-0 
Recommendations among Children and Adolescents in the United States. The Journal of 
Pediatrics. 2016 Aug; 175: 188–194. 
 
Heshmat R, Qorbani M, Babaki A, Djalalinia S, et al. Joint Association of Screen Time 
and Physical Activity with Cardiometabolic Risk Factors in a National Sample of Iranian 
Adolescents: The CASPIANIII Study. PLoS One. 2016 May 11; 11(5): e0154502. 
 
Hidalgo-Santamaria M, Fernandez-Montero A, Martinez-Gonzalez M, et al. Exercise 
Intensity and Incidence of Metabolic Syndrome: The SUN Project. American Journal of 
Preventive Medicine. 2017 Jan 9. [epub ahead of print]. 
 
Huang PL. A comprehensive definition for metabolic syndrome. Disease Models and 
Mechanisms. 2009; May–Jun; 2 (5–6): 231–237. 
 
Hukkanen J, Jacob III P, Benowitz N. Metabolism and Disposition Kinetics of Nicotine. 
Pharmacological Reviews. 2005 May; 57(1): 79–115. 
 
International Diabetes Federation. The IDF Consensus Definition of the Metabolic 
Syndrome in Children and Adolescents. International Diabetes Federation. 2007. 
 
Jepsen P, Skriver MV, Floyd A, et al. A population-based study of maternal use of 
amoxicillin and pregnancy outcome in Denmark. British Journal of Clinical 
Pharmacology. 2003 Feb; 55(2): 216–221. 
 
Jornayvaz1 FR, Vollenweider P, Bochud M, et al. Low birth weight leads to obesity, 
diabetes and increased leptin levels in adults: the CoLaus study. Cardiovascular 
Diabetology. 2016 May 3; 15:73. 
 
Kalliomaki M, Collado M, Salminen S, Isolauri E. Early differences in fecal microbiota 
composition in children may predict overweight. American Journal of Clinical Nutrition. 
2008 Mar; 87(3): 534–538. 
 
  
130 
Korn E, Graubard B. Analysis of Large Health Surveys: Accounting for the Sampling 
Design. Journal of the Royal Statistical Society. Series A (Statistics in Society). 1995; 158 
(2): 263–295.  
 
Korn E, Graubard B. Epidemiologic Studies Utilizing Surveys: Accounting for the 
Sampling Design. American Journal of Public Health. 1991 Sept; 81 (9): 1166–1173. 
 
Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC growth charts for the United States: 
Methods and development. National Center for Health Statistics. Vital Health Statistics. 
Series 11, Data from the national health survey. 2002 May; (246): 1–190. 
 
Kum-Nji P, Meloy L, Herrod H. Environmental Tobacco Smoke Exposure: Prevalence 
and Mechanisms of Causation of Infections in Children. Pediatrics. 2006 May; 117 (5): 
1745–1754. 
 
Laursen A, Kristiansen O, Marott J, et al. Intensity versus duration of physical activity: 
implications for the metabolic syndrome. A prospective cohort study. BMJ Open. 2012 
Oct 8; 2(5): e001711. 
 
Ley RE, Turnbaugh P.J, Klein S, Gordon JI. Microbial ecology: Human gut microbes 
associated with obesity. Nature. 2006 Dec 21; 444(7122): 1022–1023. 
 
Martino F, Puddu P, Lamacchia F, Colantoni C, et al. Mediterranean diet and physical 
activity impact on metabolic syndrome among children and adolescents from Southern 
Italy: Contribution from the Calabrian Sierras Community Study (CSCS). International 
Journal of Cardiology. 2016 Dec; 225: 284–288. 
 
McConnell R, Shen E, Gilliland F, Jerrett M, et al. A Longitudinal Cohort Study of Body 
Mass Index and Childhood Exposure to Secondhand Tobacco Smoke and Air Pollution: 
The Southern California Children’s Health Study. Environmental Health Perspectives. 
2015 Apr; 123(4): 360–366.  
 
McGregor JA, French JI, Parker R, et al. Prevention of preterm birth by screening and 
treatment for common genital tract infections: Results of a prospective controlled 
evaluation. American Journal of Obstetrics and Gynecology. 1995 Jul; 173(1): 157–167. 
 
Million M, Maraninchi M, Henry M, Armougom F, et al. Obesity-associated gut 
microbiota is enriched in Lactobacillus reuteri and depleted in Bifidobacterium animalis 
and Methanobrevibacter smithii. International Journal of Obesity (Lond). 2012 Jun; 
36(6): 817–25. 
 
Mitchell AA, Gilboa SM, Werler MM, et al. Medication use during pregnancy with a 
particular focus on prescription drugs: 1976–2008. American Journal of Obstetrics and 
Gynecology. 2011 Jul; 205(1): 51.e1–51.e8. 
  
131 
 
Mueller NT, Rifas-Shiman SL, Blaser MJ, et al. Association of prenatal antibiotics with 
foetal size and cord blood leptin and adiponectin. Pediatric Obesity. 2017 Apr; 12(2): 
129–136. 
 
National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, 
Evaluation and Treatment of Overweight and Obesity in Adults. NIH Publication. 1998; 
98-4083.  
 
Nelson J, Werler M. Socioeconomic Status as a Modifier of the Relationship between 
Antibiotic Use During Pregnancy and Birthweight. Birth. 2008 Sept; 35(3): 196–203. 
 
Neto A, Campos W, Santos G, Junior O. Metabolic syndrome risk score and time 
expended in moderate to vigorous physical activity in adolescents. BMC Pediatrics. 2014 
Feb; 14: 42. 
 
Ogden CL, Carroll MD, Fryar CD, et al. Prevalence of Obesity Among Adults and 
Youth: United States, 2011–2014. NCHS Data Brief. 2015 Nov; 219; 1–8. 
 
Ogden CL, Carroll MD, Kit BK, et al. Prevalence of Obesity in the United States, 2009–
2010. NCHS Data Brief. 2012; 82. 
 
Oken E, Kleinman K, Rich-Edwards T, et al. A nearly continuous measure of birth 
weight for gestational age using a United States national reference. BMC Pediatrics. 2003 
Jul 8; 3:6. 
 
Oldroyd J, Renzaho A, Skouteris H. Low and high birth weight as risk factors for obesity 
among 4 to 5-year-old Australian children: does gender matter? European Journal of 
Pediatrics. 2011 Jul; 170(7): 899–906. 
 
Pagani L, Nguyen AK, Fitzpatrick C. Prospective Associations Between Early Long-
Term Household Tobacco Smoke Exposure and Subsequent Indicators of Metabolic Risk 
at Age 10. Nicotine and Tobacco Research. 2016 May; 18(5): 1250–1257. 
 
Peplies J, Bornhorst C, Gunther K, et al. Longitudinal associations of lifestyle factors and 
weight status with insulin resistance (HOMA-IR) in preadolescent children: the large 
prospective cohort study IDEFICS. International Journal of Behavioral Nutrition and 
Physical Activity. 2016 Sept; 13(1): 97. 
 
Prince RL, Kuk JL, Ambler KA, et al. Predictors of Metabolically Healthy Obesity in 
Children. Diabetes Care. 2014 May; 37(5): 1462–1468. 
 
  
132 
Sallis J, Buono M, Roby J, et al. Seven day recall and other physical activity reports in 
children and adolescents. Medicine and Science in Sports and Exercise. 1993 Jan; 25 (1): 
99–108. 
 
Steur M, Smit H, Schipper C, Scholtens S, et al. Predicting the risk of newborn children 
to become overweight later in childhood: The PIAMA birth cohort study. International 
Journal of Pediatric Obesity. 2011 Jun; 6(2–2): e170–e178. 
Sung RYT, Yu CW, Chang SKY, et al. Effects of dietary intervention and strength 
training on blood lipid level in obese children. Archives of Disease in Childhood. 2002 
Jun; 86: 407–410.  
 
Toschke AM, Montgomery SM, Pfeiffer U, von Kries R. Early Intrauterine Exposure to 
Tobacco-inhaled Products and Obesity. American Journal of Epidemiology. 2003 Dec 1; 
158 (11): 1068–1074. 
 
U.S. Department of Agriculture and U.S. Department of Health and Human Services. 
Dietary Guidelines for Americans, 2010. 7th Edition, Washington, DC: U.S. Government 
Printing Office, December 2010. 
 
U.S. Department of Health and Human Services, Public Health Service, National 
Institutes of Health, and National Heart, Lung, and Blood Institute. National Cholesterol 
Education Program. ATP III Guidelines at a Glance Quick Desk Reference. NIH 
Publication No. 01-3305. May 2001. 
 
U.S. Department of Health and Human Services. 2008 Physical Activity Guidelines for 
Americas. <www.health.gov/paguidelines> Accessed April 2014. 
 
Vidal AC, Murphy SK, Murtha AP, et al. Associations between antibiotic exposure 
during pregnancy,birth weight and aberrant methylation at imprinted genes among 
offspring. International Journal of Obesity. 2013 Jul; 37(7): 907–913. 
 
von Kries R, Toschke A, Koletzko B, Slikker W. Maternal Smoking during Pregnancy 
and Childhood Obesity. American Journal of Epidemiology. 2002 Nov 15; 156(10): 954–
961. 
 
Weight gain during pregnancy. Committee Opinion No. 548. American College of 
Obstetricians and Gynecologists. Obstetrics and Gynecology. 2013 Jan; 121(1); 210–212. 
 
Weitzman M, Cook S, Auinger P, et al. Tobacco Smoke Exposure is Associated with the 
Metabolic Syndrome in Adolescents. Circulation. 2005 Aug 9; 112(6): 862–869. 
 
Xie B, Palmer P, Pang Z, et al. Environmental tobacco use and indicators of metabolic 
syndrome in Chinese adults. Nicotine and Tobacco Research. 2010 Mar; 12(3):198–206. 
 
  
133 
Yau W-P, Lin K-Y J, Werler MM, et al. Drug Certainty-Response in Interview Based 
Studies. Pharmaceoepidemiology and Drug Safety. 2011 Nov; 20(11): 1210–1216. 
 
Zaren B, Lindmark G, Bakketeig L. Maternal smoking affects fetal growth more in the 
male fetus. Paediatric and Perinatal Epidemiology. 2000 Apr; 14(2): 118–126. 
 
Zlatohlavek L, Hubacek JA, Vrablik M, et al. The Impact of Physical Activity and 
Dietary Measures on the Biochemiocal and Anthropometric Parameters in Obese 
Children. Is There Any Genetic Predisposition? Central European Journal of Public 
Health. 2015 Nov; 23(Suppl): S62–S66. 
  
134 
CURRICULUM VITAE 
                      
  
135 
 
 
 
  
136 
 
 137 
  
138 
